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ABSTRACT 
Cervical adenocarcinoma (ADC) represents about 20% of invasive cervical cancers. 
Implementation of screening programs that have led to a decrease in squamous cell 
carcinoma (SCC) has only had a limited preventive effect on adenocarcinoma as the 
incidence of ADC, especially among younger women, has steadily increased in recent 
decades. Human papillomavirus (HPV) is considered the most important single factor 
for development of SCC. Adenocarcinomas of the cervix are also related to HPV of 
high risk types (HR-HPV), but the correlation is less pronounced. HPV infection alone 
is insufficient and other factors are required for oncogenic transformation to ADC.  
The aim of this thesis is to investigate molecular markers such as tumor suppressor 
p16INK4a, proliferation marker Ki-67, possible tumor suppressor proteins in the LRIG 
family, the TP53 target WIG-1, and E6/E7 mRNA in cervical adenocarcinoma in order 
to provide a deeper understanding of the etiology of the disease and to develop more 
efficient screening strategies for adenocarcinoma of the cervix. 
Formalin-fixed/paraffin-embedded tumor tissue samples of cervical ADC were 
investigated by immunohistochemistry (IHC) for the occurrence of p16INK4a using the 
CINtec® kit, of Ki-67 with the MIB-1 antibody, and of LRIG1, LRIG2 and LRIG3 
using polyclonal rabbit antibodies. In 38 samples of cervical cancer (ADC or SCC), 
Wig-1 was examined by IHC using a monoclonal antibody. In cervical cancer cell lines 
the WIG-1 gene locus was investigated by SKY, CGH, Southern and FISH; mRNA 
expression by Northern and RT-PCR; and protein expression by Western analysis. 
Testing for E6/E7 mRNA was carried out using the PreTect HPV Proofer; testing for 
HR-HPV DNA was done by consensus PCR and subsequent typing by SSCP, direct 
sequencing and Linear Array®. The examined markers were evaluated regarding 
prognostic impact and association with HPV infection. 
We found that poorly differentiated tumors stain with less intensity and in a lower 
fraction than do well differentiated tumors. All HPV-positive tumors showed p16INK4a 
staining, but 60% of HPV-negative tumors also stained for p16INK4a. We found a 
significant correlation between staining for Ki-67 and histological grade (p=0.031) as 
well as worse outcome (p=0.004).  
High staining intensity for LRIG1 and a high fraction of LRIG3-positive cells were 
significantly associated with improved patient survival (p=0.03 and p=0.04). LRIG1 
and LRIG3 expression correlated with HPV infection, since higher staining intensity 
was observed in HR-HPV-positive cases.   
mRNA extraction from paraffin-embedded tissue samples was successful, as shown by 
positive results in the GAPDH mRNA integrity control in all cases. HR-HPV infection 
was detected by mRNA in 64% of the tumors, compared with detection by DNA in 
62% of the tumors. There was an 87% agreement in results between the two methods 
regarding HPV positivity and 84% agreement regarding HPV type. 
WIG-1 is not the primary target for genomic alteration on chromosome 3, even though 
analysis revealed chromosome 3 gains in all lines. WIG-1 mRNA expression was 
  
higher in the two HPV-negative cervical cell lines (C33-A, HT-3) than in the HPV-
positive lines. Wig-1 expression in tumor tissue, as assessed by IHC, showed 
significantly higher nuclear Wig-1 levels in ADC than in SCC (p<0.0001). We 
observed higher nuclear Wig-1 expression in the HPV-negative tumors than in HPV-
positive tumors (p = 0.002). Patients with tumors that demonstrated moderate nuclear 
and positive cytoplasmic Wig-1 expression had a better prognosis (p = 0.042) than 
those with high nuclear and negative cytoplasmic Wig-1 expression.  
According to our findings the tested markers appear to be potential diagnostic 
supplements for cervical adenocarcinoma as expression of Wig-1 as well as LRIG1 and 
LRIG3 could serve as prognostic markers, p16INK4a and Ki-67 might be helpful markers 
for grading endocervical malignancies and mRNA testing has been shown to be as 
sensitive as DNA testing. The combination of improved detection of precursors through 
integration of molecular markers into screening programs with vaccination against 
HPV 16 and 18 will help cervical cancer including adenocarcinoma to become one of 
the most preventable cancers. 
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1 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Livmoderhalscancer är den tredje vanligaste tumörtypen hos kvinnor i hela världen. 
Det finns två olika former av livmoderhalscancer beroende på vilka celler som 
omvandlas till cancer. I Sverige, liksom i många andra utvecklade länder, har 
förekomsten av skivepitelcancer i livmoderhalsen minskat dramatiskt de sista 
årtiondena, till följd av gynekologisk screening med cellprover sedan 60-talet. Trots 
detta drabbas ca 450, till övervägande del unga kvinnor, av livmoderhalscancer och 150 
kvinnor dör årligen av sin sjukdom. När det gäller adenocarcinom i livmoderhalsen 
(mindre vanlig form, ca 20 % av alla tumörer i livmoderhalsen, som utgår från 
körtelepitelceller) har däremot inte någon minskad frekvens observerats utan snarare en 
stegring, främst hos yngre kvinnor. Adenocarcinom har inte samma tydliga förstadium 
som skivepitelcancer, och det ger sig inte lika ofta till känna vid screeningen. 
Diagnostiken som bedrivs inom dagens rutinsjukvård, cytologprovet, är ett otillräckligt 
screeninginstrument för att upptäcka adenocarcinom i tidigt skede, och ger tyvärr ofta 
otillräcklig information. Idag vet vi att livmoderhalscancer orsakas av ett virus, humant 
papillomvirus (HPV), som sprids sexuellt. Vidare vet vi att HPV är en av de vanligaste, 
om inte den vanligaste, sexuellt överförbara sjukdomen bland unga individer i världen 
idag. Detta gör livmoderhalscancer till en av de vanligaste cancerformar bland kvinnor 
i världen. Humant papillomvirus (HPV) av s.k. “högrisk typ” är en förutsättning för 
utveckling av livmoderhalscancer och nästan 100 % av skivepitelcancer har visats 
innehålla ”högrisk” HPV, men ytterligare faktorer bidrar till cancerutvecklingen. 
Adenocarcinom innehåller HR-HPV i 70-80% av alla fall. Det visade sig att det fanns 
HPV-16 och HPV-18 i normala cytologiska prover 14 år innan diagnosen av 
adenocarcinom ställdes. HPV typning som komplement skulle kunna öka möjligheten 
att upptäcka adenocarcinom i tidigt skede, främst hos unga kvinnor, en grupp som 
oftast har HPV-positiva tumörer.   
 
Målet med denna avhandling var att undersöka molekylära markörer i fall av 
adenocarcinom och deras relation till HPV samt prognosen av cancersjukdomen. Nya 
känsliga och specifika tester som skulle kunna förbättra den gynekologiska 
hälsokontrollen är av största värde.  
 
I det första delarbetet analyserade vi 101 arkivprover av tumörvävnad från 
adenocarcinom i livmodertappen, med avseende på expression av p16INK4a (en 
tumörhämmare) och Ki-67 (en tillväxt markör), och resultat relaterades till HPV-
infektion och stadie av cancer och den mikroskopiska tumörbilden. Vi fann att tumörer 
som var lågt differentierade uttryckte cancer markören p16INK4a i mindre utsträckningen 
och med lägre intensitet än de högt differentierade tumörer. Alla tumörer som innehåll 
HPV, och även 60 % av tumörer utan HPV infektion uttryckte p16INK4a . Dessutom 
fann vi ett starkt samband mellan Ki-67 och den mikroskopiska tumörbilden. Sämre 
prognos var förknippat med högre Ki-67 uttryck.  
 
Den andra studien undersökte värdet av olika metoder för detektion av HPV infektion. 
Mätning av HPV mRNA av de fem vanligaste typerna som tecken på expression av 
tumörbefrämjande gener jämfördes med resultat från HPV DNA mätningen hos 
kvinnor med adenocarcinom. Vi visade att denna metod hade ungefär samma 
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känslighet som HPV DNA metoden, E6/E7 mRNA av de 5 HR-HPV typer uppvisades 
i 64 % av tumörerna jämfört med HPV DNA som vi fann bara i 62 % av alla tumörer. 
Resultat mellan metoderna överenstämde i 87 %.  
 
Den tredje delarbete testade hypotesen om att påvisande av LRIG1, 2 och 3 i 
tumörvävnader skulle kunna användas som en prognostisk markör hos patienter med 
adenocarcinom i livmodershalsen. Vi fann att hög immunfärgning för LRIG1 och 
LRIG3 var förknippat med förbättrad överlevnad och det fanns ett samband mellan 
uttrycket av LRIG1 och LRIG3 och HPV infektion.  
 
I den fjärde studien undersökte vi WIG-1. Det är en av de gener som kan uppregleras 
av TP53 (en s.k. tumörhämmare och ha en central roll för att skydda oss mot cancer), 
men WIG-1 kan också själv reglera TP53. Vi undersökte därför uttryck av Wig-1 
protein i livmoderhalscancer och fann kraftigare uttryck av proteinet i körtelcellcancrar 
än i skivepitelcancrar. Vi hittade högre uttryck i cellkärnor hos HPV-negativa tumörer 
jämfört med HPV-positiva tumörer.  
 
Adenocarcinom i livmoderhalsen är en svår diagnostiserad sjukdom. Att påvisa 
korrelation mellan förändringar i cancercellen och kliniskt förlopp av tumörsjukdomen 
är önskvärt. Socialstyrelsen har förordat införande av vaccin för flickor mellan 10-12 
års ålder redan hösten 2008. Vaccination mot HPV är ett nytt effektivt verktyg som 
kommer att utgöra första steget i den kedjan av åtgärder som ingår i prevention av 
livmoderhalscancer. För första gången ges möjlighet till effektiv primärprevention av 
livmoderhalscancer, men vaccinet kommer inte att skydda mot alla virustyper. Därför 
är det desto viktigare att fånga upp kvinnor som löper risk för adenocarcinom, genom 
att hitta tidiga markörer för snabb och inriktad prevention, vilket är hela detta projekts 
utgångspunkt.   
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2 BACKGROUND 
2.1 THE CERVIX 
The uterine cervix is the lower part of the uterus (Figure 2-1) and is composed of dense 
fibro muscular tissue. The outer part of the cervix protrudes into the vagina. It mainly 
functions as a sphincter (especially during pregnancy), a barrier to prevent ascending 
infections and a source of lubricating mucous.  
The outside of the cervix is called the ectocervix and the inner portion is called the 
endocervix. The ectocervix is covered by nonkeratinized stratified squamous 
epithelium (Figure 2-2a), while the endocervix is covered by a single layer of mucin-
secreting columnar epithelium (Figure 2-2b). The cervical canal runs through the 
cervix. The internal os is where the canal opens into the uterus and the external os is 
where it opens into the vagina.   
 
Figure 2-1 Anatomy of the human uterus.                                                                            
(taken from http://global.britannica.com/EBchecked/topic/620603/uterus) 
 
 
Figure 2-2 Stratified squamous epithelium (a); columnar epithelium (b); taken from 
IARC (http://screening.iarc.fr/colpochap.php?chap=1). 
a b 
 4 
 
2.1.1 Transformation zone (TZ ) 
The original squamocolumnar junction (SCJ) between squamous and columnar 
epithelium, called the congenital junction, remains unchanged until puberty. Post 
puberty, in addition to the congenital junction, the adult or functional junction forms 
and is termed the new SCJ. The columnar epithelium is exposed to the acid, non-sterile 
environment of the vagina and will gradually be replaced by squamous epithelium 
through a process known as metaplasia (Schiffman et al. 2007), which occurs in the 
transformation zone (TZ).  The TZ occupies the area between the original and the new 
SCJ and becomes larger with age as it expands toward the cervical opening (Figure 
2-3).  
 
Figure 2-3 Transformation zone with original and current squamocolumnar junction in 
an adult woman; taken from: Herzog et al. 2007. 
The TZ plays a crucial role in the pathogenesis of cervical cancer (CC). It is assumed 
that oncogenic HPV infect reserve cells of the TZ that are committed to glandular 
differentiation, which eventually leads to the proliferation of glandular lesions and AIS 
(Herzog et al. 2007; Doorbar et al. 2012). A special target cell in the squamocolumnar 
junction with embryonic characteristics has been described. This cell is highly 
susceptible to oncogenic HPV DNA incorporation and is speculated to be strongly 
related with cervical carcinogenesis (Herfs et al. 2012). 
2.2 CERVICAL CANCER  
2.2.1 Histology, clinical features and diagnosis 
There are two major histological types of cervical cancer, one derived from each of the 
two different types of cervical epithelium: squamous cell carcinoma (SCC) and 
adenocarcinoma from glandular cells (ADC). The highest incidence of cervical cancer, 
80-95%, is attributable to SCC. ADC accounts for 5–20% of all cervical cancers (Jemal 
et al. 2011). ADC may be categorized into further subgroups such as mucinous and 
non-mucinous adenocarcinoma. The most common histological type of invasive 
adenocarcinoma is mucinous adenocarcinoma. There are also carcinomas composed of 
a mixture of malignant glandular and squamous cells, known as adenosquamous 
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carcinoma, and in very rare cases, cancer may even arise from other types of cervical 
cells (IARC publications chapter 5). 
The cardinal symptom of invasive cervical cancer is abnormal bleeding. In addition, 
vaginal discharge and in advanced cases, pelvic or lower back pain and/or sciatic nerve 
root pain radiating into the lower extremities may occur. The presence of bowel or 
urinary symptoms would indicate advanced late-stage disease. Clinical suspicion of 
cervical cancer requires work-up that includes biopsy or diagnostic conization for a 
definitive histological diagnosis. Once the diagnosis is confirmed, the stage of the 
disease needs to be ascertained to determine a suitable treatment plan. The International 
Federation of Gynecology and Obstetrics (FIGO) has formulated a widely used and 
recommended system as described in 
Table 2-1 (Pecorelli et al. 2009; Quinn et al. 2006). 
 
FIGO stage Extension of tumor 
Stage I Carcinoma confined to the cervix. 
IA Microinvasive carcinoma, not clinically visible. Can only be diagnosed by 
microscopy. 
IA1 Stromal invasion <3mm in depth and <7 mm horizontal spread  
IA2 Stromal invasion ≥3≤5 mm in depth and < 7 mm horizontal spread 
IB Carcinoma clinically visible; or a microscopic lesion greater than IA2 
IB1 ≤4 cm in greatest dimension 
IB2 ≥4 cm 
Stage II Carcinoma spread beyond the cervix, but not as far as the lower third of the 
vagina or the pelvic wall 
IIA1▪ Tumor size <4 cm with involvement of less than the upper two-thirds of the vagina, 
but not extending to tissues surrounding the uterus (parametria). 
IIA2▪ Tumor size ≥4 cm with involvement of less than the upper two-thirds of the vagina 
and without invasion of parametria. 
IIB Parametrial invasion, but not as far as the pelvic wall or the lower third of the 
vagina. 
Stage III Tumor extends to pelvic wall or involves the lower third of the vagina, or 
causes hydronephrosis or non-functioning kidney 
IIIA Extension to the lower third of the vagina,  with no extension to the pelvic wall, 
and no hydronephrosis or non-functioning kidney 
IIIB Extension to the pelvic wall, with hydronephrosis or non-functioning kidney. 
Stage IV Tumor has spread. 
IVA Spread to involve the mucosa of the bladder or rectum. 
IVB Spread to distant organs, such as extrapelvic lymph nodes, kidneys, skeleton, lungs, 
liver and brain. 
 
Table 2-1 Summary of the FIGO stages (WHO, 2006) ▪ Subdivision of Stage IIA 
according to Pecorelli et al, 2009. 
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2.2.2 Epidemiology 
Currently, cervical cancer ranks third among the most common female malignancies 
(after breast and colorectal cancer) with an estimated 530,000 new cases and 275,000 
cancer deaths in 2008 (de Martel et al. 2012). Incidence varies immensely between 
different regions, with the highest risk seen in Eastern and Western Africa where age-
standardized rates (ASR) are >30/100,000, while the lowest risk is seen in Western 
Asia, North America and Australia where ASRs are <6/100,000. More than 85% 
(450,000 cases) of the global burden of cervical cancer occurs in developing countries, 
where the majority of women have little or no access to preventive screening and 
adequate treatment nor, more recently, to HPV vaccination (GLOBOCAN 2008, Figure 
2-4).  
 
 
Figure 2-4 Global map showing the estimated age- standardized cervical cancer incidence 
rate per 100,000 worldwide in 2008; taken from GLOBOCAN 2008, IARC 
(http://globocan.iarc.fr/factsheet.asp). 
Incidence and mortality rates of CC in countries with well-organized screening 
programs have decreased significantly since the introduction of screening. In Sweden 
the incidence of CC has declined from 20 cases per 100,000 women in 1965 and seems 
to have leveled off with a rate of approximately 7 cases per 100,000 since the late 
1990s (The National Board of Health and Welfare 2012). In the 35-39 year age group, 
the National Swedish Cancer Registry shows a drop in age-specific rate from 46.0 per 
100,000 women in 1958 to 15.5 in 2004 – a 66% reduction. In the 70-74 year age group 
the rate dropped from 27.0 to 11.4 – a 42% reduction. The Swedish Cause of Death 
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Register shows an age standardized mortality rate of 7.7  per 100,000 women for CC in 
1959 and 2.8 in 2004 (Pettersson et al. 2011). 
In contrast to rates for squamous cell cervical carcinoma, the incidence rates of cervical 
adenocarcinoma have steadily increased in developed countries in women born in 1930 
and in successive cohorts thereafter through the mid-1960s (Gustafsson et al. 1997, 
Vizcaino et al. 2000). The age-adjusted incidence rates for ADC increased throughout 
Europe and ranged from ~0.5 to >3% per year (Vizcaino et al. 1998; Bray et al. 2005). 
This upward trend, noted particularly among women under age 40, has occurred despite 
extensive Pap smear screening (Vizcaino et al. 1998; Visioli et al. 2004; Bray et al. 
2005, Bergström et al. 1999; Wang et al. 2004). 
The Swedish National Cancer Registry shows an increase in incidence of ADC in the 
25-29 year age group from 0.7 per 100,000 for women born between 1935 and 1939, to 
1.2 per 100,000 for women born between 1950 and 1954. In the 30-34 year age group a 
similar increase was seen from 1.0 for women born between 1930 and 1934 to 1.9 for 
women born between 1945 and 1949 (Pettersson 1998). A subsequent study also 
showed a twofold increase in incidence of ADC during a 35 year period (Bergström et 
al.1999). 
Studies have shown that SCC and ADC of the cervix seem to share most risk factors. 
However, our understanding of the epidemiology and natural history of CC may still be 
incomplete.  
The strong link between infection with HPV 16 or 18 and malignant transformation of 
the glandular epithelium of the cervix suggests that screening for these two HPV types 
might be a useful tool for improving prevention and/or early detection of cervical 
adenocarcinoma, which has proven to be difficult through regular cytological screening 
(Sasieni et al. 2009). It was recently estimated that Swedish women who did not 
undergo regular cytological screening had a modest 60% increased risk of being 
diagnosed with cervical adenocarcinoma, but a 200% increased risk of squamous cell 
carcinoma, compared with women who participated in screening. Thus cytological 
screening provides substantially lower protection against adenocarcinoma than 
squamous cell cancer of the cervix (Andrae et al. 2008). 
An increase of in-situ forms has preceded the decrease of invasive cancer for squamous 
lesions. Paradoxically, the rising incidence of AIS over the past decades has 
corresponded with an increase in ADC rates (Hemminki et al. 2002; Wang et al. 2004; 
Sherman et al. 2005). 
2.2.3 Risk factors 
As early as the nineteenth century, the association between cervical cancer and sexual 
activity was suggested by the absence of cervical cancer among nuns (Rigoni 1987). 
Research to demonstrate the possible role of HPV in cervical cancer began in 1974-
1976 (z. Hausen 2009) and eventually garnered the Nobel Prize in 2008. The first 
papilloma virus types were isolated 35 years ago (Orth et al.1977) and in 1983 a new 
type was isolated from cervical cancer tissue and called human papillomavirus type 16 
according to order of discovery (Dürst et al. 1983). Sexually transmitted HPV is now 
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recognized as playing a causative role in the development of cervical cancer (Munoz 
2000). By the last decade, HPV had been detected in almost all (99.7%) cervical 
cancers (Walboomers et al. 1999).  
Although HPV infection is necessary for development of cervical cancer, that alone is 
insufficient, because the majority of HPV-infected women do not develop cervical 
cancer. Since the establishment of the causative role of HPV infection, previous risk 
factors for cervical cancer have now been redefined as surrogate markers for risk of 
HPV or as important cofactors (Bosch et al. 2002). 
Lifetime number of sexual partners is a surrogate marker, highly correlated with HPV 
exposure and thereby cervical cancer. The International Collaboration of 
Epidemiological Studies of Cervical Cancer (ICESCC) conducted a reanalysis showing 
that risk of cervical cancer increases with total number of sexual partners. A lifetime 
history of >6 partners doubles risk, while >11 partners triple risk, compared with 
women who had only one partner. However, risk of becoming infected with HPV 
depends on many factors, including the sexual behavior of the partner (ICESCC 2009). 
First intercourse at an early age also increases risk of cervical cancer, which is subject 
to a variety of interpretations. Early first intercourse may be a marker of high-risk 
behavior and also of more HPV infections. According to another interpretation, early 
first intercourse may increase duration of HPV infections, which could be more 
harmful. A third interpretation may be that the cervix is more susceptible to HPV 
infection in young women (ICESCC 2009). 
Medium (5-9 years) or long-term use (>10 years) of combined estrogen-progestin 
contraceptives is considered to be a co-factor. Combined oral contraceptives are 
classified by the IARC as carcinogenic factors because they increase the risk of cervical 
cancer, as well as breast and hepatocellular cancer (Cogliano et al. 2005). A large 2007 
reanalysis of 24 studies, showed a twofold increase for developing cervical cancer 
among current medium-term and long-term users which declines after use ceases 
(ICESCC 2007). Use of combined oral contraceptives is not believed to increase 
susceptibility to HPV infection, for which reason the increase in risk appears to be 
associated with established HPV infection (Cogliano et al. 2005). However, no 
significant difference between women with and without HR-HPV infection was found 
in the reanalysis study (ICESCC 2007). 
The IARC also classifies smoking as a carcinogenic factor for cervical cancer (Secretan 
et al. 2009). According to the ICESCC, smoking increased the risk of invasive cervical 
cancer (ICC) or carcinoma in situ (CIS)/ cervical intraepithelial neoplasia 3 (CIN 3), 
where relative risk (RR) of 1.60 was found compared with never-smokers. Risk was 
also increased for former smokers, though less so than among current smokers (RR: 
1.12). However, the increase in risk for current and former smokers applied only to 
SCC and was not demonstrated for ADC (ICESCC 2006). 
Another co-factor for development of cervical cancer analogous to exogenous 
hormonal use is high parity. The risk of cervical cancer increases with the number of 
full-term pregnancies. An IARC study of HPV-positive women demonstrated a 
fourfold risk among women with more than 7 full-term pregnancies, compared with 
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nulliparous women, while risk among women who had only one or two full-term 
pregnancies was doubled (Bosch et al. 2002). 
Herpes simplex type 2 (HSV-2) infection was found to double risk of SCC and triple 
risk of ADC in an IARC study of HPV-positive women (Smith et al. 2002a, de Sanjose 
et al. 1994). One Swedish cohort study showed that women with prior history of 
Chlamydia trachomatis infection were at increased risk (RR: 2.09) of HPV persistence, 
but no such correlation was demonstrated for HSV-2 (Silins et al. 2005). Chlamydia 
trachomatis infection also doubled risk of SCC, but no association was found with 
ADC (Smith et al. 2002b). 
A case-control study showed that prevalence of cervical cancer in HPV was higher 
among HIV-infected women. The explanation for the increased prevalence may relate 
to immunosuppression causing persistent infection, as well as to riskier sexual behavior 
among HIV-positive women, which in turn may be associated with greater risk of other 
STIs such as HPV (Odida et al. 2011). However, subjecting the data concerning cancer 
incidence among HIV-positive women and patients receiving immunosuppressive 
treatment, such as transplant recipients, to meta-analysis showed that both these groups 
were more likely to develop infectious disease-related cancers, including HPV-related 
cancers. Similar patterns among patients with HIV infection and patients with 
iatrogenic immunosuppression suggest that immunosuppression, rather than other risk 
factors may be responsible for the increased risk of cancer (Grulich et al. 2007; Frisch 
et al. 2000). An inverse association between degree of neoplasia and interleukin-2- 
production in response to HPV-16 E6 and E7 proteins has been observed (Tsukui et al. 
1996). As well as an impaired T-helper cell response been discussed to predispose for 
the progression of cervical disease (Hildesheim et al. 1997). 
Genetic predisposition is another proposed co-factor for cervical cancer. In 1999, data 
from a Swedish register study could supply first evidence for a significant familial 
clustering of cervical cancer which is likely to result from genetic rather than 
environmental factors. The results were not specified for histological type (Magnusson 
et al. 1999). Subsequent studies supported the hypothesis of hereditary co-factors 
(Czene et al. 2002; Zelmanovic Ade et al. 2005; Hemminki et al. 2006; Couto et 
al.2006). 
Differences in Co-factors between SCC and ADC 
Some heterogeneity in the co-factors may be associated with adenocarcinoma. 
According to Castellsague et al., cofactors having a statistically significant positive 
association with ADC and HPV-positive cases included long-term use of OCs and very 
high parity. IUD use was shown to have a protective effect (Castellsague et al. 2006). 
In contrast to SCC, several studies found no association between smoking and 
incidence of cervical ADC (Green et al. 2003; Plummer et al. 2003; ICESCC 2006; 
Berrington de Gonzalez et al. 2004). Nor was any correlation confirmed between age at 
first birth and ADC (Berrington de Gonzalez et al. 2004). In a small sample Lacey 
noted that unopposed estrogens used in HRT were independently associated with ADC 
(Lacey et al. 2000). Obesity was also found to have a stronger association with ADC 
than SCC (Lacey et al. 2003). 
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2.2.4 Precancerous lesions of the cervix 
Precursor lesions of SCC are divided into CIN stages 1, 2 and 3 based on histological 
appearance, according to the classification system developed by Richart. This 
classification is based on the proportion of atypical cells and disruption of architecture, 
which reflects the severity of the lesion. CIN 1 represents mild dysplasia with atypical 
cells in the lower third of the epithelium and intact stratification, CIN 2 is characterized 
by moderate dysplasia with atypical cells in two thirds of the epithelium, while CIN 3 is 
associated with severe dysplasia or the equivalent of CIS, with atypical cells throughout 
the entire epithelium. ICC is defined as penetration of the epithelial basement 
membrane by atypical cells (Richart 1973).  
In the 1990s a supplementary classification system, the Bethesda system, was 
introduced by the National Cancer Institute in the United States. This system is based 
on cytology, where low-grade squamous intraepithelial lesions (LSIL) correspond to 
CIN 1 and high-grade squamous intraepithelial lesions (HSIL) correspond to CIN 2 and 
3, because of the difficulty in distinguishing between them using cytology. Moreover, 
the Bethesda system includes nomenclature for cells that cannot be designated as LSIL, 
yet still demonstrate atypical appearance. It differentiates between atypical squamous 
cells – uncertain significance (ASC-US) and atypical squamous cells – cannot exclude 
HSIL (ASC-H) (Solomon et al. 2002). 
2.2.4.1 Adenocarcinoma in situ (AIS) 
Since the glandular epithelium of the cervix is a monolayer, there is no such stepwise 
division of potentially precancerous lesions. The Bethesda system discriminates 
between atypical glandular cells, atypical glandular cells- favour neoplastic and 
endocervical adenocarcinoma in situ (AIS).  
AIS is a relatively rare condition that has not drawn as much attention as precursor 
lesions originating in the squamous epithelium of the cervix. AIS is known to occur 
beneath the transformation zone and may thus be covered by normal metaplastic or 
dysplastic epithelium.  
An abundance of evidence supports cervical adenocarcinoma in situ as a precursor of 
invasive cervical adenocarcinoma (Zaino 2002). AIS lesions are frequently found 
immediately adjacent to invasive adenocarcinoma (Boon et al. 1981). Cases of 
untreated AIS preceding invasive adenocarcinoma have been reported (Boon et al. 
1981; Poynor et al. 1995) and the duration of progression from AIS to ADC has been 
estimated at 5-13 years (Lee et al. 2000; Plaxe et al. 1999). In fact, with a mean age at 
diagnosis of about 35-39 years, AIS is diagnosed in an age group 10-20 years younger 
than invasive ADC (Ostör et al. 2000, Azodi et al. 1999, Boon et al. 1981). 
Similar HPV types dominate in both AIS and invasive ADC. A recent investigation by 
Andersson et al. found that HPV 18/45 were clearly predominant, followed by HPV16 
in (Andersson et al. 2013). Data regarding multifocal lesions are controversial. True 
multifocality has been described in 13-15% of cases (Ostör et al. 2000; Jaworski 1990). 
Coexistence with squamous cell lesions is a frequently observed phenomenon in 
glandular lesions. Zaino described concurrent squamous lesions with AIS in 
approximately 50% of cases (Zaino 2002), while more recent studies reported even 
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higher rates of up to 64-90% (Andersson et al. 2013; Ault et al. 2011). Furthermore, 
AIS multicentricity has been reported in ~15% of patients (Jaworski 1990). In about 
50% of cases, AIS is diagnosed only because of detection of a squamous lesion (Ostör 
et al. 2000; Ault et al. 2011; Andersson et al. 2013).  A study reported the same HPV 
types in AIS and in the adjacent squamous mucosa (Tase et al. 1989). 
2.2.5 Natural history of precancerous lesions 
The risk of developing CIS or ICC is cumulative in relation to severity of dysplasia. A 
review based on follow-up studies of women with abnormal cytology between 1950-
1990 presented the natural history of CIN and showed that CIN 3, diagnosed by biopsy 
in women who were left untreated and only followed up by cytology, turned into 
invasive cancer in an estimated 30%-50% of cases (Ostör 1993; McCredie et al. 2008). 
A more recent large Canadian retrospective cohort study based on cytology samples 
collected between the 1960s and 1980s, during which time CIN management was 
relatively conservative, showed that 10% of mild dysplasia progressed to severe 
dysplasia or worse within 10 years, compared with 32% for moderate dysplasia. The 
study also showed that the majority of all mild dysplasia would spontaneously regress. 
The regression ratio (first normal Pap smear) for mild dysplasia was 44% within 2 
years and 88% within 10 years. The ratio for spontaneous regression of moderate 
dysplasia was lower, but 83% still regressed within 10 years (Holowaty et al. 1999).  
2.2.6 Treatment and prognosis 
Treatment protocols for SCC and ADC are similar and the therapy is based on the 
FIGO clinical staging system. High-grade preinvasive lesions and FIGO stage IA 
cancer are treated by conization or radical hysterectomy with excellent results. Tumors 
diagnosed in more advanced stages are treated with radiation therapy alone or 
concomitantly with chemotherapy using cisplatin-based regimens. A Cochrane review 
of 19 randomized controlled trials (RCTs) involving locally-advanced cervical cancer 
confirmed benefit on overall and progression-free survival with use of platinum-
containing chemotherapy regimens together with radiation therapy (Stern et al. 2012; 
Green et al. 2005). 
Data on prognosis of ADC compared with SCC remain equivocal. For carcinoma 
diagnosed with lymph node metastasis, Nakanishi et al. found that prognosis was worse 
for ADC than for SCC. However, in the absence of lymph node metastases, no 
difference was seen (Nakanishi et al. 2000). A similar conclusion was drawn from a 
literature review in which survival rates for patients with small tumors in the absence of 
lymphovascular involvement were comparable for ADC and SCC. With advancing 
tumor stage, survival rates for ADC were significantly lower than for SCC (Gien et al. 
2010). In contrast, a population-based analysis from the US found lower survival rates 
for ADC in both early and advanced stages (Galic et al.2012). The incidence of distant 
metastasis is higher for ADC than for SCC (Eifel et al.1995), as is the uncommon 
finding of ovarian metastasis (5.3% vs. 0.8%) (Shimada et al. 2006).   
Andrae et al. found a significantly better prognosis among women diagnosed through 
screening compared with those diagnosed because of symptoms, which is largely 
attributable to the earlier stage at which cancer is detected by screening. The authors 
investigated all cases of cervical cancer occurring in Sweden over a 3-year period with 
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follow-up at 8.5 years and found no significant difference in prognosis for SCC or 
ADC (Andrae et al. 2012). Analyses of HPV type though indicate a significantly poorer 
prognosis for HPV-18 associated tumors, particularly adenocarcinomas (Im et al. 
2003), which the authors attribute to deeper cervical invasion and greater pelvic lymph 
node involvement. 
2.2.6.1 Discriminating primary cervical and endometrial adenocarcinoma 
Due to topographical proximity it can sometimes be challenging for the pathologist to 
reliably discriminate primary endocervical adenocarcinoma from endometrial 
adenocarcinoma, which originates from the mucosa of the corpus uteri. However, the 
confident distinction between the two is of substantial clinical and prognostic 
importance. In cases of unequivocal histological assessment a panel of markers is 
applied which includes staining for estrogen receptor (ER), vimentin, monoclonal 
carcinoembryonic antigene (CEA) and p16INK4a. The panel may be completed with 
HPV testing and p53 staining. 
In most cases primary cervical adenocarcinoma is CEA positive and vimentin negative 
as well as negative or focally weak positive for ER. HR-HPV is present in a high 
percentage and thereby diffuse p16INK4a staining is common. ‘Wild-type’ p53 is more 
likely to be found in cancers originating from the cervix (McCluggage 2013). 
2.2.7 Screening 
The goal of well-organized screening programs, including treatment of detected 
precancerous lesions, is to prevent invasive cancer. Since cervical cancer develops 
slowly over 10-15 years, screening programs are essential for early detection and 
treatment of neoplasia (Sankaranarayanan et al. 2006).  
2.2.7.1 Screening methods 
2.2.7.1.1 Exfoliative cytology 
Pap smear 
Pap smear cytology, named for developer, the Greek pathologist Dr. George 
Papanicolaou, has long been in use and is still the screening method recommended by 
the WHO. Exfoliating cells taken from the ectocervix with a spatula and from the 
endocervix with a brush are directly smeared onto a slide, fixed in ethanol and air dried. 
After multichromatic staining the slide is examined under a microscope.  
Although Pap smear screening greatly reduces the incidence of cervical cancer, the 
sensitivity of the test is low, with an overall detection rate of 50% to 60% (Schiffman et 
al. 2011). A systematic review of 94 studies showed that sensitivity ranged between 
30% and 87% and specificity between 86% and 100% (Nanda et al. 2000). Due to the 
low accuracy of the Pap smear and the many false-negative results, alternative methods 
are currently under evaluation. 
Liquid-based cytology (LBC) 
Liquid-based cytology (LBC) is a new method, introduced in the 1990s, in which 
similarly sampled exfoliating cervical cells are preserved in liquid and then smeared 
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onto a slide and stained with the Papanicolaou stain. LBC produces more uniform 
samples, thereby facilitating exact morphological interpretation. Unsatisfactory sample 
quality with the need for repeat sampling is substantially decreased when using LBC 
compared to conventional smear (Ronco et al. 2007; Strander et al. 2007). 
The outstanding advantage of the method is the possibility for supplementary analysis 
such as HPV testing or immunocytochemical methods on the same sample. The so 
called ‘reflex test’ refers to the subsequent HPV testing on the same sample if the 
cytology is assessed as abnormal. 
The method has been adopted in some countries, though only in high-income settings 
due to high cost. Studies comparing efficacy of LBC with conventional cytology show 
conflicting results. A meta-analysis evaluated the sensitivity and specificity in detecting 
CIN 2+ and found comparable results for LBC and conventional cytology (Arbyn et al. 
2008) as did other studies (Ronco et al. 2007; Siebers et al. 2009). 
According to WHO, LBC provides higher sensitivity than conventional cytology 
(WHO 2006), and there are other studies that have confirmed its superiority Schiffman 
et al. 2011; Strander et al. 2007; Davey et al. 2007).         
2.2.7.1.2 HPV testing 
HPV testing is method to detect viral DNA as the precondition for development of 
cervical cancer. Some studies show that HPV testing is more sensitive for detection of 
CIN 3 than conventional cytology. The greatest advantage of HPV testing, however, is 
the high negative predictive value for development of cervical cancer among HPV 
DNA-negative patients. This advantage is important for risk stratification of patients 
and it is also cost-effective because it allows the screening interval to be prolonged in 
HPV-negative women (Schiffman et al. 2011). HPV testing for primary screening is 
still controversial, mainly due to its lower specificity, especially in young women 
(Ronco et al. 2010). In a large review of routine screening data from more than 60,000 
North American and European women, the sensitivity of HPV testing for detection of  
CIN2+ was unambiguously higher than for cytology (96.1% vs. 53.0%). As expected, 
specificity was lower for HPV testing than for cytology (90.7% vs. 96.3%), although 
this parameter improved with increasing age (Cuzick et al. 2006). Primary HPV testing 
with cytology triage was more sensitive in detecting CIN 3+ than primary cytology 
alone (Anttila et al. 2010).  A multinational cohort study by Dillner et al. found that a 
negative baseline HPV test had a significantly higher negative predictive value for 
developing CIN3 or cancer than a negative baseline cytology (Dillner et al. 2008). 
2.2.7.1.3 Visual screening methods 
Visual screening methods in colposcopy include visual inspection with acetic acid 
(VIA) and Lugol’s Iodine (VILI). Application of acetic acid to the cervix turns 
abnormal cells white, while iodine turns them dark-yellow. Average sensitivity is 77% 
and specificity 86%. Instant results and low cost make VIA a promising screening 
option in low-income settings. However, further research, including RCTs, is needed to 
compare VIA, which is currently recommended only for pilot projects with 
conventional cytology (WHO 2006). 
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2.2.7.2 Organized screening 
The Swedish national screening program notifies all women aged 23 to 49 to come for 
a Pap smear every third year and women aged 50 to 60 to come every five years, which 
complies with WHO recommendations with the exception of age at initiation 
(Stockholm County Counsil 2011, Vårdprogramm). 
In Sweden, organized screening for cervical cancer has been introduced in 1964 and 
fully established in 1974. The introduction of organized screening showed great impact 
on the incidence of cervical SCC whereas the incidence of ADC was rather 
uninfluenced (Bergström et al.1999). Women who belong to the screening generation 
were diagnosed at an earlier stage than those of the prescreening generation (55% 
compared to 17% at stage I). Likewise, the proportion of advanced cases, stages III and 
IV, dropped from 29.3% to 21.2% (Pettersson et al. 2011). 
The effectiveness in reducing mortality (>60%) was demonstrated in a Swedish 
population-based study. The study concluded that non-adherence to screening programs 
was the major cause of mortality in cervical cancer. Thus screening programs are 
presumably the key to reducing the incidence of cervical cancer (Jemal et al. 2011; 
Andrae et al. 2008). 
A rather new approach to increase coverage of cervical cancer screening is self-
sampling. The woman collects a vaginal sample herself with a simple device and sends 
it to the laboratory for HPV testing. As self-sampled material does not reliably contain 
cells representing the transformation zone it is not suitable for cytological assessment. 
The approach of self-sampling increases participation in organized screening (Sanner et 
al. 2009) and shows reliable results in detecting precancerous lesion (Brink et al. 2006; 
Sanner et al. 2009). 
2.2.7.3 Screening for adenocarcinoma 
Detection and treatment of in situ cancers are more effective at preventing SCC than 
invasive ADC, as confirmed by the observation that the vast majority of cervical cancer 
cases in poorly screened populations are SCC. In contrast, regions with good cervical 
cancer screening programs have a higher proportion of ADC (Schiffman et al 2007). 
However, a Swedish study from 2008 found that screening also has an effect on the 
incidence of ADC. The authors concluded that the increasing incidence of 
adenocarcinoma is the net result of increases in background risks, such as acquisition of 
HPV infection, and the counteracting effect of screening programs is unable to keep 
pace improving outcomes (Andrae et al. 2008). 
There is overwhelming evidence that a remarkable percentage of AIS fails to be 
detected by cytological screening, or may progress rapidly to invasion. 
Adenocarcinomas frequently occur among women who underwent screening within 5 
years of diagnosis (Hildesheim et al. 1999; Andersson et al. 2003). A negative cytology 
report affords less assurance against development of adenocarcinoma than squamous 
carcinoma (Mitchell et al. 1995).   
Inadequate screening results may be due to compromised sample quality secondary to 
the less-than-adequate devices and techniques used to obtain the sample (Herzog et al. 
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2007). The introduction of cytobrush techniques, which allow sampling in the cervical 
canal, and of liquid-based cytology, which provides a monolayer of cells for 
assessment, were the first steps toward more accurate sampling and diagnoses of 
glandular lesions (Ashfag et al. 1999).  
The location of glandular lesions and thereby the limited access for colposcopic 
assessment amplifies the challenges in diagnosing precursors of ADC. Irregular 
distribution of abnormalities within glands, the small size of some lesions and 
multifocality can further hamper assessment.  
Inadequately validated cytological criteria for neoplasm precursors have been 
suggested to be a possible reason for screening deficiencies concerning glandular 
lesions, thereby subjecting results to a wide variation of inter-observer interpretation. A 
minor improvement in specificity could be made through subtype characterization, 
given the increasing possibility of identifying histological subtype over time (Gunnel et 
al. 2007). 
 
2.3 HUMAN PAPILLOMAVIRUS 
2.3.1 Classification of papillomaviruses 
Papillomaviruses (PV) belong to the Papillomaviridae family of DNA viruses. They 
display high diversity and are able to infect all kinds of mammals, as well as birds and 
reptiles. To date well over 200 types of PV are known. The L1 gene encodes for the 
major viral L1 capsid protein, which together with the L2 protein constitute the 
complete capsid. Overall, L1 is the most conserved open reading frame (ORF) of the 
PV genome. Sequence comparisons of whole genomes lead to a similar distribution of 
interrelated HPV types as found when comparing the L1 ORFs (de Villier et al. 2004). 
Papillomaviruses are classified in taxonomic levels including genus, species (due to 
close phylogenetic relationship between certain types and because the concept species 
typically lumps PV types with common biological and pathological properties), types 
(a newly discovered papillomavirus type is defined as a complete papillomavirus 
genome, whose L1 gene nucleotide sequence is at least 10% different from that of other 
known papillomavirus types), subtypes (the L1 gene sequence differs by 2-10%) and 
variants (the L1 gene sequence is no more than 2% dissimilar) (Bernard 2013). 
Human papillomaviruses are PV with the capacity to infect humans. Members of this 
multifaceted group have different epithelial tropisms and life-cycle strategies. Most 
types are ubiquitous with global distribution where different types dominate in different 
areas (Doorbar et al. 2012). Isolation and characterization of new HPV types is an 
ongoing process; currently 170 HPV types have been identified (deVilliers 2013; 
Bernard 2013; Figure 2-5). 
HPV are members of 5 PV genera: the alpha-, beta-, gamma-, mu-, and nu-
Papillomaviruses. Alpha-PV is divided into cutaneous and mucosal types according to 
epithelial tropism. A total of 40 sexually transmitted types have been detected in the 
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anogenital mucosal epithelium. These are clinically further divided into high-risk and 
low-risk types according to their potential to mediate human carcinogenesis (Wise 
Draper et al. 2008; Doorbar et al.2012).  The WHO classifies the following 12 types as 
high risk: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59. Several other types, such as 
types 68 and 73, belong to the high-risk clade and are classified as “possibly cancer-
causing” because of their similarity to cancer-causing types, even if they have not been 
found in cancer. Even low-risk types may occasionally be associated with cancer 
(Doorbar et al. 2012). There are also putative high-risk types, such as HPV 26, 53, and 
66 (IARC Monographs 2007; Munoz et al. 2003). Although the life-cycle organization 
of high-risk types shares many similarities with low-risk HPV, the two groups differ 
significantly in their ability to drive cell cycle entry and cell proliferation. 
 
 
Figure 2-5 Phylogeny of  papillomavirus types based on the nucleotide sequence of the L1 
gene; taken from Bernard 2013. 
 
2.3.2 Genome structure and viral particle  
HPV is a small non-enveloped DNA virus containing almost 8000 base pairs. Circular 
double-stranded DNA is surrounded by a protein shell composed of two structural 
proteins, the major capsid protein L1 and the minor L2. 
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The genome is functionally divided into 3 domains: the long control region (LCR) and 
eight genes that are divided into early and late regions according to the order of the 
action of these genes in the viral life cycle (Figure 2-6). The LCR is a non-coding 
upstream regulatory region of 400 to 1000 base pairs. It contains promoter, enhancer 
and silencer sequences that regulate replication by controlling the transcription of the 
open reading frames (ORF). This region contains the highest degree of variation in the 
viral genome. The early region consists of six ORFs: E1, E2, E4, E5, E6, and E7. These 
genes are involved in regulation of replication and transcription, cell growth and 
maturation and virus release, as well as malignant transformation. The late region 
encodes the structural proteins L1 and L2 for the viral capsid, which is exclusively 
produced in the fully differentiated cells in the top layers of the epithelium (Burd 2003; 
Bernard 2013). 
 
 
Figure 2-6 Schematic depiction of the genome organization of human papillomavirus 
type 16; taken from  Doorbar J et al. 2012.  
 
E1:   E1 protein is the initiator of viral DNA replication. It acts as an ATPase 
and DNA helicase and binds to DNA polymerase. 
E2:   E2 protein is the main regulator of viral gene transcription. It modulates 
viral gene expression, has multiple binding sites in the viral LCR, binds the viral 
transcriptional promoter, and interacts with E1 to locate the viral origin of replication. 
E2 mediates down-regulation of E6/E7 transcription, which results in undisturbed 
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function of p53 and pRb proteins and allows the life cycle of the host cell to progress 
normally. Integration of HPV DNA into the host cell genome disrupts E2, which leads 
to reduced down-regulation of E6/E7 and thereby to increased expression of E6/E7 
(McBride 2008). 
E4:   E4 protein acts late in the viral life cycle and accumulates at very high 
levels in cells that support virus synthesis. It facilitates assembly, maturation and 
release of virus particles, interacts with the keratin cytoskeleton and intermediate 
filaments, and induces arrest in the G2 phase of the cell cycle.   
The E5, E6, and E7 gene products have proliferative properties and mediate 
progression to malignancy. HPV oncoproteins cause DNA damage as well as both 
numerical and structural chromosome instability during HPV-associated carcinogenesis 
(Duensing et al. 2002). They do not possess enzymatic activities themselves, but 
instead interact directly or indirectly with a number of cellular target proteins (Wise 
Draper et al. 2008). Deregulation of E6 and E7 expression is the critical event in 
neoplastic dedifferentiation; their action is more efficient when the two act in concert, 
but even high levels of E7 alone are adequate (Burd 2003).   
E5:  E5 induces aberrant cell proliferation by stimulating cell growth through 
stabilization of growth factor receptors (EGFR, PDGFR beta and CSF1R), by 
enhancing EGF signaling and by inhibiting apoptosis (Genther et al. 2003). E5 
interferes with intracellular trafficking of endocytotic vesicles (IARC Monographs 
2007). The E5 gene sequence is deleted when viral DNA is integrated into host cells 
(Schwarz et al. 1985). E5 inhibits transport of major histocompatibility complexes to 
the cell surface and thereby helps the virus to evade immune response. 
E6:  E6 codes for a small protein of approximately 150 amino acids that 
contains two zinc finger motifs. HR-HPV E6 protein is found both in the nucleus and 
cytoplasm (Moody et al. 2010; Howie et al. 2009). HR-HPV E6 has been shown to 
block apoptosis, promote proliferation, activate telomerase, and to disrupt cell 
differentiation, adhesion and polarity, as well as to reduce immune recognition (Howie 
et al. 2009).  
The E6 protein disrupts both the extrinsic and intrinsic pathways of p53 dependent 
apoptosis as well as p53 independent apoptosis (Howie et al. 2009). It interacts with 
tumor suppressors, especially p53, abrogating its normal function including cell cycle 
arrest in G1, activation of DNA repair and induction of apoptosis. E6 induces 
degradation of p53 through complex formation and induction of proteolysis via 
ubiquitin ligase (Wise Draper et al. 2008), blocks the specific binding site of p53 and 
can relocate p53 to the cytoplasm where it cannot carry out transcription (Howie et al. 
2009). Degradation of p53 is specific to the HR-HPV E6 protein (Wise Draper et al. 
2008). 
E6 exerts its proliferative effect by interacting with transcriptional activators and 
inducing DNA synthesis; it prevents cell differentiation and interacts with factors 
involved in cell polarity and motility. 
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Activation of telomerase contributes to immortalization of malignant cells. Telomerase 
is activated in many cancer cells, but remains quiescent in most normal somatic cells. 
E6 can activate telomerase in epithelial cells independent of p53 (Klingelhutz et al. 
1996; Wise Draper et al. 2008; Howie et al. 2009) 
All these mechanisms in concert result in genomic instability, accumulation of mutated 
cells and development of malignant phenotypes. Moreover, E6 has been shown to help 
the virus to avoid the immune defenses by interacting with two proteins that are part of 
the innate immune response to viral infection: Interferon regulatory factor-3 (IFR-3) 
and Toll-like receptor 9 (TLR9) (Ronco et al. 1998; Hasan et al. 2007; Howie et al. 
2009).  
E7: E7 encodes a protein of approximately 100 amino acids mainly localized 
to the nucleus, although some studies have suggested that E7 also has a cytoplasmic 
component (Moody et al. 2010; Mc Laughlin-Drubin et al. 2009). E7 is the major 
transforming protein needed for maintenance of a transformed phenotype. E7 induces 
abnormal cell proliferation, interacts with histone acetyl transferases and interacts with 
negative regulators of the cell cycle and tumor suppressors, primarily the 
retinoblastoma (Rb) family.  
The tumor suppressor proteins of the Rb family are major targets of E7. So-called 
pocket proteins are phosphor proteins that usually repress E2F transcription factors, 
which are key regulators of S-phase genes (Wise Draper et al. 2008; Moody et al. 
2010). Binding of E7 inactivates Rb by disrupting the complex between pRb and E2F, 
which leads to liberation of E2F. E2F action on the methyltransferase gene exposes a 
gene sequence, allowing transcription of genes required for the S-phase of the cell cycle 
(Burd 2003), resulting in stimulation of cell cycle progression and proliferation. Both 
HR-HPV and LR-HPV E7 proteins can interact with Rb, but the binding affinity of 
HR-HPV E7 is many times greater than that of LR-HPV E7 (Münger et al. 1992). See 
Figure 2-8 on page 36. 
E7 proteins also alter cell cycle control through interactions with cyclins and the cyclin-
dependent kinase inhibitors p21 and p27, which are critical for cell cycle arrest in 
response to DNA damage (Moody et al. 2010). 
L1:  L1 is the major viral structural protein component in the assembly of 
capsomeres and capsids. It plays a key role in viral entry into the host cell and interacts 
both with cell receptors and L2. L1 is expressed exclusively in non-transformed cells 
and is highly immunogenic.  
L2:  L2 is a large protein, albeit a minor component of the viral capsid. It 
facilitates cell entry, genome encapsidation and intracellular endosomal trafficking of 
virions to the nucleus, and plays a role in capsid stabilization.  
(reviewed in IARC Monographs 2007) 
2.3.3 Viral life cycle 
Human papilloma virus is an obligatory intracellular parasite. Since HPV genomes do 
not encode enzymes necessary for viral replication they are dependent on the 
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replication capacity of a mitotically active cell (Moody et al. 2010; Pyeon et al. 2009). 
The human papilloma virus must deliver its genome and accessory proteins into the 
host cell and use the biosynthetic cellular machinery for viral replication. Consequently, 
HPV’s productive life cycle is restricted to terminally differentiating epithelium 
(Schiller et al. 2010).  
Infection with HPV requires epidermal or mucosal epithelial cells that are able to 
proliferate (z. Hausen 1996). In multilayer epithelium, those cells are located in the 
basal layer, which is accessible through tiny tears in the epithelium (Schiffman et al. 
2007). One area especially prone to infection and severe lesions is the previously 
mentioned transformation zone. 
This area is characterized by increased accessibility and proliferation of the basal cell 
layers, especially during puberty and onset of sexual activity (Doorbar et al. 2012). 
Cells close to the squamous columnar junction, such as epithelial reserve cells or 
columnar epithelial cells, may be associated with development of adenocarcinoma 
(Doorbar et al. 2012). 
Papillomaviruses are the only viruses known to initiate the infectious process at an 
extracellular site (Schiller et al. 2010). The virus gains access through micro wounds to 
the basement membrane of the disrupted epithelium, where it initially binds. Only after 
it binding to the basal keratinocyte cell surface can the virus gain subsequent entry 
(Scheelhaas et al. 2008). 
Virus entry is achieved through the following steps:   
Via its major capsid L1 protein, HPV interacts with heparan sulfate proteoglycans 
(Giroglou et al. 2001) on the epithelial surface or the basement membrane (Raff et al. 
2013). Heparan sulfate proteoglycans (HSPG) are considered the primary attachment 
receptors (Joyce et al. 1999; Sapp et al. 2009). In addition to cell surfaces, PV capsids 
bind to the ECM via HS and Laminin-5 (Culp et al. 2006). This primary attachment 
process is solely dependent on L1 and does not require L2 (Horvath et al. 2010). 
Binding of HPV triggers structural changes in the virion capsid that affect both L1 and 
L2; specifically, the binding exposes the N-terminus of L2 to proteolytic cleavage. 
These changes expose the binding site of a secondary uptake receptor on the surface of 
basal epithelial cells. This interaction is necessary for virus internalization and 
subsequent transfer of the viral genome to the nucleus (Richards et al. 2006; Selinka et 
al. 2007; Day et al. 2008; Kines et al. 2009). 
At the same time HPV binds to alpha 6 integrins, which initiates further intracellular 
signaling events. HPV 16 has been shown to bind to a newly identified L2-specific 
receptor, the Annexin A2 heterotetramer, which triggers endocytosis (Woodham et al. 
2012; Raff et al. 2013). 
Following receptor interaction, the virus is internalized by endocytosis. At this point, 
the various viral types use different pathways. Regardless of pathway, the process 
occurs slowly over a period of several hours (Schiller et al. 2010, Raff et al. 2013). 
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Once internalized, virions probably undergo endosomal transport and uncoating in 
endocytic vesicles. L1 is shed from the viral genome and ultimately subjected to 
lysosomal degradation. Prior to transport from endosome to nucleus along 
microtubules, disassembly of the viral particle occurs (Schelhaas et al. 2012; Florin et 
al. 2006). 
The L2 protein DNA complex ensures correct nuclear entry of the viral genomes. Cell 
division is needed to establish and express the viral genome in the nucleus (Pyeon et al. 
2009). Entry of the viral genome into the nucleus may follow from nuclear membrane 
breakdown during mitosis, rather than through active transport (Darshan et al. 2004). 
Initially, inside the proliferative host cell, the HPV genome is replicated at low, non-
productive levels using the host cell DNA replication machinery. During this phase 
both virus and host cell replicate together. Viral copy number is maintained at low 
levels of about 50-200 copies per cell (Pyeon et al. 2009, McBride 2008).  
The infected basal cells divide and their daughter cells migrate toward the epithelial 
surface. As long as cells continue to divide, expression of viral proteins is tightly 
controlled. E6 and E7 are expressed at very low levels. (z Hausen 2002;  Stanley et al. 
2012). As cells reach the upper epithelial layer, they stop dividing and instead 
differentiate into mature epithelial cells. The virus switches to DNA amplification 
mode; all viral genes (including “late genes”) are activated and the circular viral 
genome is replicated in high copy numbers, while structural proteins are also 
synthesized. The genomes are encapsidated and the assembled virions are released 
along with the most superficial dying and detaching epithelial cells (z Hausen 2002).  
E4 is thought to control virion release and infectivity in the upper epithelial layer 
(Doorbar et al. 2012).  
The full viral cycle takes a long time, and even in the optimal scenario the time from 
cell entry to virus release takes about 3 weeks, since this is the time required for basal 
keratinocytes to move up through the epithelium, where they are sloughed off.  
Eventually, large numbers of infectious virus are shed for transmission to naive 
individuals (Stanley et al. 2012). 
2.3.4 Methods of detection  
2.3.4.1 Polymerase chain reaction (PCR) 
The two HPV detection methods currently in large- scale- use are PCR and the Hybrid 
Capture (HC) test. PCR has high analytical sensitivity and is able to detect as few as 10 
copies of HPV genomic DNA in a few microliters of specimen. This method 
selectively targets a DNA sequence through a set of consensus (GP5+/6+, 
PGMY09/11) primers directed at a conserved region within the L1 gene, and is capable 
of detecting virtually all mucosal HPV types. Commercially available PCR-based 
detection systems include Amplicor and Linear Array by Roche, CH. Amplicor allows 
detection of 13 HPV types in a cocktail (similar to HC), although it is not able to 
perform genotyping. The Amplicor test has 93-95% sensitivity for detecting 
HSIL/CIN2+, which is equal to that of HC2 (Mo et al. 2008; Monsonego et al. 2005).  
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Linear Array allows detection and typing of 37 HPV types using a nylon strip covered 
with immobilized type-specific oligonucleotides. The method is faster than other 
genotyping methods, but is not yet suitable for high-throughput. 
Luminex-based HPV genotyping is a novel technique that combines PCR amplification 
with hybridization to fluorescence-labeled polystyrene bead microarrays. The detection 
limit for the various HPV types is above 500 plasmids and the results from this 
technique are in excellent agreement with an established microarray chip (Oh et al. 
2007). 
2.3.4.2 Hybrid capture (HC) 
HC is a high-throughput, semi-automated test approved by the U.S. Food and Drug 
Administration (FDA). HCII is a refinement of HCI, and permits detection of 13 HR-
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) and 5 LR-HPV types (6, 
11, 42, 43, 44) with a cut-off limit of 5000 HPV genomes per reaction. The LR-HPV 
and HR-HPV probe cocktails are used in separate reactions. 
2.3.4.3 Other methods 
After PCR amplification, HPV DNA can also be detected by Southern blot, in which 
the PCR products are separated by electrophoresis on an agarose gel and transferred 
onto a nylon membrane, which is hybridized with type-specific probes. This method 
has been considered the gold standard for evaluation of HPV genomes, since it is 
specific, able to determine the physical status of the genome (episomal or integrated), 
and semi quantitative. A simplified version without gel separation is dot blot or slot blot 
hybridization, in which PCR product (single-stranded DNA) is directly applied to a 
nylon membrane for hybridization with type-specific probes.  
Another method for relative HPV typing is single-strand conformational 
polymorphism. PCR is performed with radioactive consensus primers and PCR 
products are separated on a non-denaturing polyacrylamide gel, where migration band 
patterns of the amplicons are compared with HPV controls. The most accurate 
technique for HPV genotyping is sequencing, which can be done directly following the 
PCR reaction or after cloning of amplified fragments (reviewed in IARC Monographs 
2007).  
2.3.5 Prevalence of genital HPV infection 
Even though HPV is a very common sexually transmitted infection, most individuals 
eliminate the infection without leaving any detectable evidence (Baseman et al. 2005). 
The virus is transmitted via intimate genital contact or contact with other mucosal 
surfaces (Moscicki et al. 2006). Acquisition of the virus peaks soon after onset of 
sexual activity. Cumulative incidence of HPV infection among young women aged 15- 
19 was found to be as high as 60% within 5 years and risk of infection increased with 
number of sexual partners (Woodman et al. 2001; Koutsky 1997; Peto et al. 2004). 
HPV is highly infectious. The incubation period ranges from 3-4 weeks to months or 
years, probably depending on dose of virus acquired (Stanley et al. 2012). The majority 
of infected individuals eventually clears the infection and becomes DNA-negative 
(Stanley et al. 2006). 
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The median duration of infections is about 8-13 months for HR-HPV, compared with 
4.8-8 months for LR-HPV (Bosch et al. 2002). Up to 50% of infections are cleared 
within 6 months, 70% within 1 year and 90% clear within 2-5 years of acquisition 
(Rodriguez et al. 2010; Winer et al. 2011; Moscicki et al. 2012; Plummer et al. 2007). 
A minority of about 10% does not effectively clear the virus, but instead remains DNA-
positive as a sign of persistent active viral infection. Persistent infection is defined as 
infection with the same viral type detected after a number of years, varying between 4 
and 12 years after initial infection. HPV-16 tends to persist longer than the average for 
other high-risk types (Franco et al. 1999). The risk for persistence increases if the 
infection has been present for >18 months, compared with newly diagnosed infections 
(Plummer et al. 2007). Persistent HR-HPV infection is requisite for development and 
maintenance, as well as progression to high-grade intraepithelial lesions (Bosch et al. 
2002; Moscicki et al .2006). Apart from persistence, the type of infection (with HPV-
16 linked to the highest risk) is an important determinant of risk for severe lesions 
(Moscicki et al. 2012). However, average persistence of HPV 16 is longer compared 
with most other HR-HPV types, which in turn may contribute to its higher cancer risk 
(Richardson et al. 2003; Franco et al.1999). 
Globally, HR-HPV is found in 10-12% of the female population (de Sanjose et al. 
2007; Bruni et al. 2010; Guan et al. 2012), with considerable variation among 
continents ranging from 8% in Asia and Europe to 24% in Africa. Prevalence is highest 
among younger women (<25 years), followed by a continuous decline that plateaus at 
30-35 years, with the exception of Mexico, Colombia and Chile, where a slight second 
increase is seen in women over the age of 45-50 (Franceschi et al. 2006; Moscicki et al. 
2012). The rate of newly detected carcinogenic HPV infections declines with 
increasing age (Rodriguez et al. 2010). Dunne et al. found the overall prevalence of 
HPV infection (including both low-risk and high-risk types) to be 26.8% among US 
women aged 14 to 59 years (Dunne et al. 2007). 
Each HPV genotype acts as an independent infection (Schiffman et al. 2007), where 
individual HR types differ enormously in their relative carcinogenic potential (Bouvard 
et al. 2009). In benign and low grade lesions due to HPV, the viral DNA is located 
extra chromosomally within the nucleus, whereas in cancer, the DNA is often found to 
be integrated in the host cell genome. To a lesser extent, viral DNA integration is also 
seen with high-grade intraepithelial lesions (IARC Monographs 2007). 
In low grade lesions, an overall HPV prevalence of 70-84% has been observed, 
depending on the investigated region. The predominant types include HPV 16 in 26.3% 
of samples, followed by HPV 31 in 11.5%, HPV 51 in 10.6% and HPV 53 in 10.2% 
(Clifford et al. 2005; Insinga et al. 2008). 
Prevalence of HR-HPV increases with severity of lesion, ranging from 12% in normal 
cytology to about 90% in CIN 3 and invasive cancer. HPV 16, 18, 45 are the only types 
that are found more frequently in invasive cervical cancer (ICC) than in normal 
cytology (Guan P et al. 2012). When retesting samples under optimal conditions that 
were initially classified as HPV-negative, Walboomers reported a worldwide 
prevalence of HPV in cervical carcinoma of 99.7% (Walboomers et al. 1999). 
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In a meta-analysis of 30,848 cases of ICC, the prevalence of all carcinogenic HPV 
types was 89.9%, a figure that reflects an increase in prevalence from 85.9% in the 
1990-1999 interval to 92.9% in the 2006-2010 interval (Li et al. 2011). Differently 
designed studies have unequivocally shown that, assuming adequate specimens, HPV 
DNA can be detected in up to 90%-100% of cases, compared with 5%-20% of cervical 
specimens from women identified as suitable epidemiological controls (Bosch et al. 
2002). 
Prevalence of HPV16 and 18 has been most widely studied since they are known to be 
the two most commonly found HPV types in cancerous lesions and are the two HPV 
types targeted by currently available vaccines. Joint prevalence worldwide of HPV 
types 16 and 18 in invasive cervical cancer is reported to be 70%-76% (de Sanjose et 
al. 2010), except for a slightly higher prevalence of 82% in Western/Central Asia and a 
slightly lower prevalence of 68% in East Asia (Li et al. 2011). However, HPV types 16 
and 18 were detected in only 52% of severe intraepithelial lesions (Smith et al. 2007). 
A Swedish study of cervical cancer cases before the introduction of the vaccine 
confirms these figures. Overall HPV prevalence for all types of cervical cancer was 
92.9%. In SCC, HPV16 and 18 were seen in 69.7% of cases (Du et al. 2011).  
Overall prevalence of carcinogenic HPV in different studies ranges from 62%-91.4% 
for ADC, compared with 87.3%-95.9% for SCC (Andersson et al. 2003; Clifford et al. 
2003; Insinga et al. 2008; deSanjose et al. 2010, Du et al. 2011; Li et al. 2011, Chan et 
al. 2012). The meta-analysis mentioned above also showed an increase in the 
prevalence of HPV for adenocarcinoma from 77.8% (1990-1999) to 86.0% (2006-
2010) (Li et al. 2011). 
In 1995, Bosch et al. reported a worldwide HPV 18 prevalence of 56% in 
adenocarcinoma, clearly making it the predominant type in these cancers (Bosch et al. 
1995). It has further been reported that HPV-18 and phylogenetically related types in 
the Alpha-7 species, such as types 39, 45 and 59, are strongly associated with cervical 
glandular intraepithelial and invasive lesions, whereas  SCC  is closely linked with 
HPV 16 and its phylogenetically related family (HPV types 31, 35, and 52) (Bosch et 
al. 2002; Clifford et al. 2008). Possibly, oncogenic potential relates to differences in 
tropism exhibited by various HPV types in different tissues. 
Recent studies indicate a tendency towards similar contributions from HPV-16 (36.3-
43.6%) and HPV-18 (36.8-41.8%) in ADC. The explanation may be related to the 
increase in joint detection of ADC and SIL, or to an increase in the percentage of 
adenosquamous carcinoma, which in turn seems to be related to HPV 16 more often 
than is ADC (Li et al. 2011; Quint et al. 2010). HPV-18 is still more commonly found 
in ADC (36.8%) than in SCC (13.2%) (Li et al. 2011).  
When comparing HPV positive women with HPV negative women with normal 
cytology, Dahlström et al. found an odds ratio (OR) of 11 for future adenocarcinoma in 
situ (AIS) and an OR of 16 for future ADC. Comparing HPV-18 positive women with 
HPV negative samples, the OR for AIS was 26.0 and for ADC was 28.0 (Dahlström et 
al. 2010).  
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Epidemiological studies suggest that the genomic variants of HPV-16 that prevail in 
different regions of the world exhibit different carcinogenic potential (Schiffman et al. 
2010), with the European variant E being most common in CIN 3 (83.8%), SCC 
(71.4%) and AIS (73.9%), while the Latin American variant AA is most common in 
ADC (41.7%), which seems to be preferentially associated with this histological type 
(Quint et al. 2010). 
With improved detection methods the observed prevalence of multiple infection 
(mostly 2, but up to 5 types) has increased from the previously reported 4%-7% to the 
current 12%-16% in invasive cervical cancer, a concurrent change which applies to the 
different  histological types (Burd 2003; Bosch et al. 2002; Li et al. 2011; Guan et al. 
2012). There is no evidence for interaction between multiple HPV types or for an 
increase in risk of malignancy due to presence of multiple infections (Plummer et al. 
2007; Bosch et al. 2002). 
2.3.6 The role of HPV in malignant transformation 
In uninfected epithelium, controlled cell division occurs in the para/basal layer. 
Regulated stimulation of cell cycle entry is controlled by growth factors such as Cyclin 
D and CDK that phosphorylate Rb.  Rb/E2F are separated and the S-phase is entered. 
Stimulated p16INK4a suppresses cyclin D/CDK through negative feedback and prevents 
overstimulation (Doorbar et al. 2012) 
Expression of the viral genome can sometimes be suppressed by epigenetic 
mechanisms such as methylation, a process that leads to persistent, but silent, infection 
where the viral genome is retained in the basal layer, but causes no apparent disease. 
Only 20% of HR-HPV infections cause morphological changes in the epithelium. 
In low-grade lesions, HPV leads to an ordered pattern of viral gene expression with 
virus life cycle entry and release of virus particles from the superficial layer. Basal cell 
proliferation is mostly regulated by growth factors, as in uninfected lesions. Viral genes 
E6/E7 promote cell cycle entry, but not proliferation, and also stimulate HPV genome 
amplification in the upper epithelial layer. E7 binds to Rb p170 and separates it from 
E2F, while E2F stimulates host gene expression, which is necessary for DNA 
replication and cell cycle progression. Most low-grade lesions will regress 
spontaneously within 18 months (reviewed in Doorbar et al. 2012).  
In high-grade lesions, a transforming infection is characterized by deregulated 
expression of viral oncogenes E6 and E7 with varying vertical expansion up to the full 
thickness of the epithelium in CIN 3. E6 and E7 stimulate additional cell cycle entry 
and proliferation. Inactivated inhibition of cell cycle progression by p16INK4a causes 
accumulation of Ki-67, MDM and finally p53 (due to decreased degradation by MDM). 
However, increased p53 cannot exert its function because it is eventually degraded by 
E6 associated with E6AP.  It is notable that certain non-carcinogenic HPV types are 
capable of producing lesions diagnosed as CIN2, which demonstrates the etiologic 
heterogeneity of these lesions (reviewed in Doorbar et al. 2012.  
Deregulated expression of the HPV oncogenes is responsible for chromosomal 
instability and accumulation of genetic errors in the infected cell, as well as the 
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eventual integration of the viral episomes into the host cell chromosome and 
progression to cancer (Wentzensen et al. 2007; Doorbar et al. 2012). Elevated E6 and 
E7 levels are directly related to increasing severity of neoplasia (Moscicki et al .2012). 
About 70% of HPV 16-associated cervical cancers contain integrated HPV-16 
sequences and in lesions due to HPV-18, the genome is almost always integrated 
(Cullen et al.1991; Badarocco et al. 2002). Cancer progression is facilitated when 
integration preserves the integrity of the long control region and the E6, E7, 5’portion 
of the E1 gene, but disrupts the regulatory E1 and E2 genes (Doorbar et al. 2012). The 
majority of cervical cancers contain one or many copies of HPV more or less randomly 
integrated (but often at fragile sites) into the host chromosome with the viral integration 
site lying within the regulatory E1 or E2 gene (Yu et al. 2005). 
The period between acquisition of infection and detection of lesions is highly variable 
and can range from weeks to months. CIN 2 may occur in young women soon after 
infection (Paavonen et al. 2007; Paavonen et al. 2009). The timeframe between onset 
of sexual activity and therefore the most likely time of acquisition of HPV and 
detectable CIN 3+ is 7-10 years (Winer et al. 2005). The average time between 
infection and establishment of a high-grade lesion is shorter than the time between the 
first small CIN 3 lesion and cancer (Schiffman et al. 2007). However, estimates are 
somewhat imprecise since we neither know the exact moment of HPV acquisition, nor 
the exact time that lesions arise due to the relatively long intervals between screenings. 
Compared with the estimated 80% lifetime risk of acquiring genital HPV infection, the 
0.03% incidence of cervical cancer in the absence of screening is very low (Parkin et 
al. 2005). About 20% of CIN I progresses to CIN 2 if left untreated (Doorbar 2006). 
CIN 2 regression rates for women <25 years are 70% for lesions induced by any HPV 
type and 50% for HPV-16 (Moscicki et al. 2010). 
2.3.7  HPV related cancer in sites other than the uterine cervix  
An estimated 12.7 million cancer cases occurred worldwide in 2008, of which 610,000 
cases (4.8%) could be attributed to HPV infection. The overwhelmingly most frequent 
of HPV related cancers was cervical cancer, accounting for 530,000 cases (86.9%) 
(Forman et al.2012). While cervical cancer is by far the most common malignant 
consequence of the carcinogenic potential of HPV infection, HPV is known to play an 
important etiological role in various other cancer entities, especially in the anogenital 
region. These include vulvar cancer, where HPV has been detected in 40%-50% of 
cases, with HPV-16 clearly being the dominant type, occurring in 80% of cases (Smith 
et al. 2009; Bosch et al. 2002). The same applies to vaginal, anal and penile cancers, 
which are HPV-positive in 65.5%, 72% and 47% of cases respectively, again with 
HPV-16 invariably being the predominant type (Smith et al. 2009; Hoots et al. 2009; 
Miralles- Guri et al. 2009). 
In recent years a causal relationship has been found between HPV and head and neck 
cancer, especially tonsil cancer. Between 13% and 56% of head and neck cancers can 
be attributed to HPV infection, with considerable variation depending on histological 
origin of lesions and global region (Forman et al. 2012, Ramqvist 2011). In HPV 
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positive oropharyngeal squamous cell cancers HPV 16 is the by far dominating type 
being detected in 90% (Ramqvist 2011). 
2.3.8 Immune response and HPV 
Host response to HPV infection mobilizes both cell-mediated and humoral immunity 
(Stanley 2010). Clearance of incident infection is mainly mediated by cellular 
immunity, while neutralizing antibodies against the L1 capsid protein protect against 
infection by preventing initial entry of the virus into the basal cell layer (Carter et al. 
1996; Stanley 2010). 
Primary immune response to HPV infection is cell-mediated and targeted against the 
early proteins, specifically E2 and E6 (Woo et al. 2010). Failure of effective cell-
mediated immune response is linked to an increased risk of progression. Some studies 
report a reduced T cell response to antigens of the respective HPV types among cancer 
patients (Welters et al. 2003; de Jong et al. 2004).  
The cell-mediated immune response is followed or accompanied by seroconversion and 
production of antibodies to the major L1 capsid protein. Whether or not serology is 
specific to HPV type and protective for a second infection is not fully clear. Transient 
infections are cleared by the innate cell-mediated immune response without creating 
memory immunity (Farhat et al. 2009).  
Seroconversion in natural infection occurs slowly, over an average of 8-9 months after 
HPV DNA is first detected and results in neutralizing antibodies to the L1 capsid 
protein. However, results are variable and antibody concentrations are low; only 50-
70% of women with incident HPV infection show type-specific seroconversion 
(Viscidi et al. 1997; Carter et al. 2000). Nevertheless, these low antibody titers seem to 
provide adequate protection against disease (Olsson et al. 2009).  
HPV successfully evades recognition by the immune system for many weeks or 
months. Due to the exclusively intraepithelial pathogenicity of HPV, the viral life cycle 
does not require a viremic phase, so viral access to vascular and lymphatic vessels and 
lymph nodes is limited. Infected cells shed virus from the epithelial surface, well 
removed from circulating immune cells. HPV is not cytolytic, but the virus replicates 
and assembles within cells that are destined for death anyway. Consequently, no 
inflammatory process occurs to alert the immune system (Stanley et al. 2012). 
A major innate antiviral mechanism, the interferon response (Pett et al. 2006), is down-
regulated by E6 and E7 in high-risk HPV through inhibition of the interferon receptor 
signaling pathway in keratinocytes (Kanodia et al. 2007). 
Despite all these mechanisms to evade host defenses, at least 80% to 90% of genital 
HPV infections resolve with time due to the cell-mediated immune response (Stanley et 
al. 2012) 
2.3.9 HPV Vaccines 
After a long period of development, two licensed prophylactic HPV vaccines are now 
available on the market. Gardasil®, a quadrivalent HPV 16, 18, 6 and 11 vaccine from 
 28 
Sanofi Pasteur MSD, has been approved in the US and Europe since 2006. Cervarix®, 
a bivalent HPV 16 and 18 vaccine from GlaxoSmithKline (GSK), was approved in 
Australia and Europe in 2007 and by the FDA in 2009.  
The vaccines are based on virus-like particle (VLP) technology. VLPs are empty non-
infectious viral shells consisting of recombinant L1 capsid protein; they are able to 
evoke an immune response without containing any viral DNA (Schiffman et al. 2007). 
These VLP vaccines are highly immunogenic, producing 50 times higher titers of type-
specific neutralizing antibodies to L1 than those produced by natural infections 
(Schiffman et al. 2007; Harper et al. 2004; Villa et al. 2006). 
This enhanced immune reaction to the VLP immunization is likely related to the route 
of administration, since VLP vaccines are given by intramuscular injection, providing 
direct access to the vascular and lymphatic system.  
Randomized controlled trials have shown that both vaccines are well-tolerated and safe 
(Lu et al. 2011). They are highly efficacious against HPV-16 and HPV-18 related high-
grade intraepithelial lesions among women aged 15 to 26, who test negative for these 
two HPV types at 5-year follow-up (Kjaer et al. 2009; Munoz et al. 2010; Lehtinen et 
al. 2012) (Paavonen et al. 2007, Paavonen et al. 2009). Even among women who tested 
seropositive but DNA-negative, as a sign of prior exposure, vaccination has proven to 
be protective in individuals up to age 25 (Munoz et al. 2010; Lehtinen et al. 2012). 
Among women with ongoing infection (seropositive and DNA positive), no benefit 
could be observed (Haupt et al. 2011). The effect on cervical cancer has not yet been 
assessed due to the long incubation period of the disease. 
Although these vaccines target the two most prevalent HR-HPV types (16 and 18), a 
significant cross-protective effect against related types HPV 31, 33, 45 and 51 has been 
demonstrated for both vaccines (Wheeler et al. 2012; Paavonen et al. 2009; Brown et 
al. 2009; Einstein et al. 2011). One concern that has occasionally been expressed is that 
by removing HPV 16 and 18, an empty ecological niche may be created for other 
oncological types to fill. Although no evidence supporting this concern has been found 
to date, long-term follow up is needed. 
In Sweden, HPV vaccination of girls aged 10-12 has been included in the national 
vaccination program since 2008. A free catch-up vaccination program is currently 
available for girls aged 13-18. Subsidized vaccination is available to women up to age 
26. 
Since HPV-16 and 18 account for about 70% of all invasive cervical cancers and the 
remaining 30% are caused by other types, the available vaccines cannot guarantee 
complete protection, despite the cross-protection phenomenon (Smith et al. 2007). 
Serrano et al. have estimated that a nine-valent vaccine targeting HPV types 31, 33, 45, 
52, and 58, as well as the types currently included in available vaccines, could prevent 
almost 90% of ICC cases worldwide (Serrano et al. 2012). A nine-valent vaccine is 
currently being tested in phase III trials.   
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A conceivable future alternative may be broad spectrum protection achieved by 
vaccination targeting L2, the minor capsid protein, which has been shown to evoke 
cross-neutralizing protection (Schiffman et al. 2007; Karanan et al. 2009). Another 
approach currently under investigation is to induce regression of established disease by 
therapeutic vaccination. Current strategies include improving access and acceptance of 
vaccines, as well as long-term follow-up to assess the effects of vaccination on the 
incidence of cancer. 
 
2.4 MOLECULAR MARKERS OF CARCINOGENESIS 
2.4.1 Viral markers of carcinogenic activity 
2.4.1.1 Viral load 
Viral load, the amount of viral DNA copies in a cell, is a quantitative test based on real-
time PCR technology that reflects the content of human DNA in the sample. Viral load 
is a surrogate for persistence (Munoz et al. 2009) and correlates with severity of disease 
(Burd 2003; Moberg et al. 2005). 
One nested case-control study found consistently higher viral loads of HPV-16 among 
cancer cases than in controls. The high viral loads detected up to 13 years before the 
diagnosis of cervical cancer reflected a 30-times higher risk of developing cervical 
cancer and a 60-times higher risk of developing carcinoma in situ, compared with 
HPV-negative women (Ylitalo et al. 2000; Josefsson et al. 2000). However, these 
results were contradicted by Lorincz et al., who found no predictive value of viral load 
for CIN3+ (Lorincz et al. 2002). Other clinically relevant findings include the 
correlation between reduction or clearance of viral load and regression of CIN lesions 
to normalcy (van Duin et al. 2002) and the predictive value of such clearance or 
reduction for harmless lesions (Snijders et al. 2006). 
So far, this method has been of limited clinical use since high viral load has been 
associated with the productive phase of infection and low viral load has been associated 
with cancer (Schiffman et al. 2007; Gravitt et al. 2007). 
2.4.1.2 E6/E7 mRNA 
Messenger RNA is the surrogate for transcription. Evaluation of mRNA from the viral 
oncogenes E6 and E7 thereby provides indirect functional information about the 
transcriptional activity of the virus. The presence of mRNA associated with viral 
oncogenes E6 and E7 is closely linked to a transforming infection and the oncogenic 
potential of the particular virus (Hudson et al. 1990; Cuschieri et al. 2008; Gravitt et al. 
2008). In 2007, Castle et al. described the correlation between detection of HPV E6 and 
E7 mRNA and severity of cervical dysplasia. They evaluated 531 liquid cytology 
samples for E6 and E7 mRNA for 14 oncogenic HPV genotypes. They found that 94% 
of women with CIN3 and 100% (5 of 5) of women with cancer tested positive for high-
risk HPV E6 and E7 mRNA activity (Castle et al. 2007).  
A prospective study from Norway compared the effectiveness of mRNA assessment 
with DNA detection to predict the risk of CIN2+ in women with atypical squamous 
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cells of uncertain significance (ASC-US) or low-grade squamous intraepithelial lesion 
(LSIL) cytology. Subsequent cytology and biopsy sampling were performed two years 
after initial HPV DNA and mRNA testing. Women with a positive high-risk mRNA 
test were about 70 times more likely to be diagnosed with CIN2+ within two years than 
women with comparable cytologic findings but a negative high-risk HPV mRNA test. 
Compared with mRNA testing, detection of HPV DNA in the same group of women 
had a 10-fold lower predictive value for CIN2+within two years than detection of 
mRNA (Molden et al. 2005). 
A meta-analysis published in 2011 showed higher specificity for detecting precursor 
lesions using RNA testing compared with DNA testing (Burger et al. 2011). RNA tests 
have even been shown to detect double-stranded (ds) DNA, albeit with substantially 
lower sensitivity (Getman et al. 2009; Boulet et al. 2010). A recent meta-analysis 
concluded that HPV assays to detect the mRNA of 5 HR-HPV types may reduce 
overdiagnosis of women with minor cytologic abnormalities. However, given the lower 
sensitivity, the authors concluded that women with negative mRNA test results cannot 
be considered free of CIN2+ and therefore require further surveillance (Verdoodt et al. 
2013). 
2.4.1.3 HPV integration status 
In contrast to precancerous lesions where HPV genomes are mainly found in an 
episomal state, high-grade lesions often present with the viral genome integrated into 
the host cell chromosome (Moody et al. 2010). Integration of viral DNA occurs at 
random sites, but fragile sites and transcriptionally active regions are preferential sites 
for integration (Ziegert et al. 2003; Wentzensen et al. 2004). Integrated viral DNA is 
found in 70% of cancers related to HPV-16, while 30% contain viral episomes. In HPV 
18-positive tumors, the viral genome is predominantly integrated (Badarocco et al. 
2002; Woodman et al. 2003). Recent studies have suggested that coexistence of HPV 
episomes with integrated copies could be crucial for carcinogenesis (Kadaja et al. 
2009). 
Whether viral integration is an early or late event—in other words, whether it is the 
cause of chromosomal instability or the result—is still open to debate.  However, 
chromosomal abnormalities have been detected in cells containing exclusively 
episomal DNA, an argument supporting integration as a rather late event in 
carcinogenesis (Wentzensen et al. 2004).  
The initial step in the integration process is disruption of the viral genome, typically at 
the E1/E2 ORF site, causing loss of important host regulatory function in these 
proteins, while the ORF of oncogenes E6 and E7 remains intact. Disruption of E2 
interferes with viral transcriptional control, leading to deregulated expression of early 
viral genes, including accelerated expression of E6 and E7 (Schwarz et al. 1985). This 
in turn leads to increased proliferative capacity, a crucial step in progression to cancer 
(Hannahan and Weinberg 2000). E6 and E7 mRNAs expressed from integrated copies 
show increased stability and integration is associated with growth advantage over cells 
containing episomal viral DNA (Jeon et al. 1995). 
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Several methods can be used to detect the integrated HPV genome. In situ 
hybridization can detect integrated viral sequences in morphological structures such as 
chromosomes or episomes (Cooper et al. 1991). PCR-based methods offer an 
alternative approach where integrated sequences are amplified together with cellular 
sequences.    
2.4.2 Host cell markers 
2.4.2.1 Genomic alterations 
Genomic instability is mandatory for malignant transformation. E6 and E7 achieve 
genomic instability through various mechanisms, such as induction of DNA damage or 
centrosome abnormalities. HPV-associated tumors harbor numerous chromosomal 
alterations, including gains or losses of whole chromosomes, or chromosomal 
rearrangements (z. Hausen 1999). Induction of genetic instability is thought to be an 
early event in the malignant process induced by HPV (Dünsing et al. 2001).  
2.4.2.2 Chromosomal aberrations 
Chromosomal copy number alteration may lead to overexpression of oncogenes or 
decreased expression of tumor suppressors. 
A recent systematic meta-analysis by Thomas et al. investigated chromosomal copy 
number alterations in HPV-positive vs. HPV-negative cancer and precancerous lesions 
in the lower genital tract, in which they compared SCC and ADC. The most frequent 
alteration in SCC was a gain of 3q, especially between 3q25 and 3q29. The frequency 
of 3q gain increased with the severity of the lesion up to 55% in cancers and was 
especially common in the presence of HPV-16. Other frequent copy number alterations 
in SCC were loss of 3p and 11q, as well as gain of 1q and 5p. The rate of alteration was 
generally lower in adenocarcinoma. Here, gain of 3q was the second most common 
alteration, exceeded only by gain of 17q and with accumulation in HPV 18-positive 
ADC (Thomas et al. 2013; Yang et al. 2001). One gene localized on 17q is ErbB2, 
which encodes the oncogenic growth factor receptor HER2/neu, which is 
overexpressed in many other adenocarcinomas. HER-2/neu has been expressed in 
cervical glandular lesions, especially in those positive for HPV-16 (Roland et al. 1997).  
An interesting gene in the frequently gained 3q is TERC (human telomerase gene, or 
telomerase RNA component), which maps to 3q26. Increased telomerase activity is 
characteristic of many cancers, including cervical cancer.  Heselmeyer et al. found 3q 
gain in 90% of SCC samples, while no gain was found among LSIL samples or those 
with normal histology. The authors therefore suspected that gain of 3q plays a key role 
in the transition from severe dysplasia to invasive cancer (Heselmeyer et al. 1996). A 
prospective study by Andersson et al. found a correlation between increasing TERC 
detection in cytology and higher grade of dysplasia (Andersson et al. 2009). TERC 
amplification in normal smears has also been shown to predict development of cervical 
SCC since 3q gain was detected in 33% of normal slides among women subsequently 
diagnosed with cervical cancer within the following 3-year period (Heselmeyer-Haddad 
et al. 2005). The same study showed that CIN1/CIN2 lesions showing a diploid pattern 
for TERC were more likely to undergo spontaneous regression, while CIN 1/CIN2 
lesions with extra copies of TERC were more likely to progress (Heselmeyer-Haddad 
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et al. 2005).  Andersson et al. examined 12 cases of ADC and found TERC gain in all 
cases (Andersson et al. 2006a). Identification of TERC amplification has the potential 
to become a useful marker for cervical cancer, including ADC. 
2.4.2.3 LRIG1,2,3 
The LRIG proteins are a family of integral surface proteins that all show a similar 
domain organization, an extracellular signal peptide composed of leucin-rich repeats 
and immunoglobulin-like domains, a transmembrane glycoprotein, and a cytoplasmic 
tail (Holmlund et al. 2004). 
The LRIG family has three members. LRIG, initially cloned in 2001 and named Lig-1, 
is located on 3p14. That region is often deleted in human cancers, including cervical 
cancer (see the chapter on chromosomal copy number alterations). LRIG1 protein 
shows similarities to Kekkon-1, an epidermal growth factor receptor antagonist in the 
Drosophila melanogaster (Nilsson et al. 2001). Expression of mRNA was found in the 
normal tissue of most organs, albeit in varying concentrations with the highest in brain 
and lowest in spleen (Nilsson et al. 2001). Interestingly, the protein was not expressed 
in the healthy uterine cervix, despite normal mRNA expression in this tissue (Nilsson et 
al. 2003). 
LRIG2, which is located on 1p13, was identified in 2003. It was found to have the same 
domain organization as LRIG1 with 47% homology in amino acid sequences.  
Similarly, LRIG2 was found to be expressed in all human tissues (Holmlund et al. 
2004). Soon thereafter LRIG3, located on 12q13, was also identified (Guo et al. 2004).  
Because of the significant structural similarities between LRIG and Kekkon-1, it was 
anticipated that LRIG would exert a tumor suppressive function through inhibition of 
epidermal growth factor receptors (EGFR) (Hedman et al. 2007). LRIG up-regulation 
is followed by ubiquitylation and degradation of growth factor receptors belonging to 
the Erb family, thereby inhibiting proliferation (Gur et al. 2004; Laederich et al. 2004). 
LRIG1 has recently been identified as an intestinal stem cell marker with tumor 
suppressor capacity (Powell et al. 2012). 
LRIG1 is down-regulated in carcinomas of the skin, cervix, bladder and lung, and 
overexpressed in astrocytoma, prostate cancer and lung carcinoid tumors (Hedman et 
al. 2007). LRIG genes are not universally down-regulated in human cancers and the 
question is whether LRIG proteins always exert a tumor-suppressive effect, or whether 
they may act as tumor promoters under certain circumstances (Hedman et al. 2007). 
In breast cancer, LRIG1 was found to be poorly expressed in ErbB2-positive breast 
cancers (Miller et al. 2008), while showing significantly higher expression in estrogen 
receptor-positive cancers compared with estrogen receptor-negative cancers. The 
results suggest that LRIG1 has an estrogen-regulated growth inhibitor function (Krig et 
al. 2001). Recent results show that both LRIG1 and LRIG3 interact with the ErbB2 
receptor, albeit with opposite results. LRIG3 increases receptor expression, thereby 
counteracting the effect of LRIG1. In turn, LRIG1 destabilizes LRIG3, thereby 
identifying it as a target for LRIG1 (Abreira et al. 2010; Rafidi et al. 2013). 
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LRIG 1 has been investigated as a prognostic marker in skin cancers: higher levels 
were associated with better survival and higher tissue differentiation, while being 
inversely related to the rate of metastasis (Tanemura et al. 2005). LRIG1 is expressed 
in various subcellular locations, such as within the nuclear, perinuclear and cytoplasmic 
compartments. In glioma, perinuclear staining was associated with lower stage, better 
survival, and lower proliferation index, and was also assessed to be an independent 
prognostic factor (Guo et al. 2006). 
As mentioned above, in contrast to mRNA, LRIG protein was not expressed in normal 
cervical tissue (Nilsson et al. 2003). Lindström et al. investigated LRIG1 expression 
together with 9 other tumor markers in 128 patients with invasive squamous cervical 
cancer. LRIG1 levels decreased with increasing stage of disease and the level 
significantly correlated with better prognosis in early stage (IB-IIA) disease. In higher 
stages, LRIG level had no predictive value (Lindström et al. 2008).  A subsequent 
study by Hedman et al. on 165 cervical cancer patients (including 36 patients with 
adenocarcinoma) found an association between expression of LRIG2 and poorer 
survival in early stage (IB-IIB) squamous cell cervical cancer. No correlation could be 
established for the relatively small sample of ADC. The authors concluded that a 
combination of high LRIG2 and low LRIG1 expression could identify women with 
very poor prognosis (Hedman et al. 2010). In the wake of these results, Lindström et al. 
investigated LRIG1 and LRIG2 together with 11 tumor markers in 171 cervical tissue 
samples (normal and CIN). Expression of both glycoproteins showed a concordant 
increase with increasing tumor grade and was associated with the tumor suppressor 
protein FHIT (Lindström et al. 2011). 
2.4.3 Expression of cellular proteins 
2.4.3.1 TP53 and WIG-1 
2.4.3.1.1 TP53 
The tumor suppressor protein that has been most extensively examined in a broad 
variety of malignancies is p53.TP53 is activated by cellular stress and responds with 
multifaceted actions such as cell cycle arrest, DNA repair and apoptosis to avert 
irreparable damage. Its function is mediated through transcriptional regulation of target 
proteins (Vousden et al. 2009). Clearly, TP53 plays an important role as tumor 
suppressor since more than 50% of human cancers contain mutation or deletion of the 
TP53 gene (Hollstein et al. 1991; Vogelstein et al. 2000; Soussi et al. 2007).  
The frequent presence of mutant TP53 seen in cervical cancer and its dependence on 
HPV infection and histological type remains controversial. Early cell line studies 
identified TP53 mutations exclusively in HPV-negative cervical cancer cells (Scheffner 
et al.1991) and this finding was confirmed by a separate study of cervical cancer tissue 
(Crook et al. 1992). Several other studies reached the conclusion that TP53 mutation is 
generally uncommon in cervical cancer, regardless of HPV status (Kessis et al. 1993; 
Busby-Earle et al. 1994). 
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Figure 2-7 Progression model of cervical carcinogenesis and biological marker levels 
(adapted from Wentzensen et al. 2007) 
 
In 2006, Andersson found mutant TP53 in 20% of cervical adenocarcinomas in a 
Swedish sample with no difference between HPV-positive and HPV-negative 
specimens (Andersson et al. 2006b). A recently published review described a higher 
rate of mutant TP53 in cervical ADC than in SCC, with remarkable geographic 
differences, where the highest frequency of mutant TP53 in ADC was found in Asia 
(19%) and Europe (12.2%) (Tornesello et al. 2013). 
In HPV-induced cervical cancer in the presence of wild-type TP53 (wt TP53), 
transformation is provoked by the interaction of the viral oncogene HPV-E6 with TP53. 
E6 forms a complex with E6-associated protein (E6AP) and together they block the 
TP53 DNA binding site and target TP53 for degradation. Inactivation of TP53 by 
mutation, deletion, or degradation leads to proliferation and immortalization of the 
affected cell (Werness et al. 1990; Scheffner et al. 1990; Scheffner et al.1991; Münger 
et al. 1992). 
2.4.3.1.2 WIG-1 
The human WIG-1 gene (wild type p53-induced gene 1; also named PAG608 and 
ZMAT3) is a direct transcriptional target gene of p53 (Varmeh-Ziaie et al. 2001). It 
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maps to chromosome 3q26.32 and encodes the Wig-1 protein that exists in two 
isoforms with either 289 or 290 amino acids (Vilborg et al. 2011). The protein contains 
3 Cys2His2-type zinc fingers, a structure shared with a few other RNA-binding 
proteins (Reuter et al. 1990).  
WIG-1 is expressed in all tissues, with the highest levels found in the brain (Vilborg et 
al. 2011). Low levels of WIG-1 mRNA and protein are found in normal human tissues, 
whereas levels may rise when wt TP53 expression is induced following activation 
(Hellborg et al. 2001). 
The fact that Wig-1 protein is mainly localized to the nucleus, but may also extend to 
cytoplasm, indicates that it can shuttle between cytoplasm and nucleus. Wig-1 
preferentially binds to dsRNA with high affinity compared with dsDNA or ssRNA 
(Mendez-Vidal et al. 2002).  
The WIG-1 promoter contains a TP53 binding site, but its expression is not exclusively 
regulated by TP53. Transcription factors other than TP53 can also regulate WIG-1, 
since WIG-1 has been detected in cells lacking TP53. Some of these transcription 
factors even promote proliferation, indicating that WIG-1 expression might be induced 
under diverse circumstances (Vilborg et al. 2011). WIG-1 can in return positively 
regulate TP53 mRNA through stabilization via a U-rich region in the p53 3’UTR 
(Vilborg et al. 2011). 
Ectopically expressed WIG-1 inhibits colony formation of tumor cells by up to 25%-
30h% (Hellborg et al. 2001), but the exact cellular mechanism of WIG-1 remains 
unknown. On the other hand, WIG-1 has been found to be amplified and overexpressed 
in squamous cell carcinoma of the lung (Varmeh-Ziaie et al. 2001) indicating a possible 
oncogenic effect.  Recently, WIG-1 was identified as a positive regulator of the N-Myc 
mRNA oncogene; knockout of WIG-1 significantly delayed N-Myc-driven tumor 
growth (Vilborg et al. 2012).  
2.4.3.2 p16INK4a 
One promising marker is the cyclin-dependent kinase inhibitor p16INK4a. This tumor 
suppressor protein inhibits E2F-dependent transcription and cell-cycle progression.  
Usually, E2F-mediated cell-cycle progression is blocked by binding of phosphorylated 
retinoblastoma (pRb) to E2F. The phosphorylation of pRb is mediated by the cyclin-
dependent kinases CDK4 and CDK6. p16INK4a exerts its effect by blocking the CDK4- 
and CDK6-mediated phosphorylation of pRb. pRb has in turn been shown to negatively 
regulate p16INK4a transcription via suppression of E2F activity (Li et al. 1994; Khleif et 
al.1996; Zhang et al. 1999), see Figure 2-8. 
In cells with transforming HPV infections and uncontrolled expression of E7, 
regulation of the Rb-E2F pathway is disrupted by aberrant E7 and activation of 
p16INK4a is unable to exert its downstream effect (Khleif et al.1996). The functional 
inactivation of Rb results in release of transcription factor E2F and cell cycle 
progression. Following the negative feedback loop between Rb and p16INK4a, 
deregulation of Rb results in hypomethylation of the p16INK4a promoter and thereby 
strong overexpression of p16INK4a, which accumulates in the cells (Sano et al. 1998; 
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Dehn et al. 2007). Continuous expression of E7 is necessary to maintain a malignant 
phenotype in HPV-associated cancer and overexpression of p16INK4a  is a direct 
consequence of this process; therefore p16INK4a becomes a surrogate marker for 
deregulated HPV oncogene expression (Khleif et al.1996). Expression of p16INK4a is 
independent of underlying HPV type, obviating the need for type specification. In 
contrast to many other tumor markers, such as Ki67, p16INK4a is not a proliferation 
marker; rather, it is associated with senescence and cell cycle arrest and is therefore not 
expressed in cells with benign proliferative capacity (Beausejour et al. 2003). 
However, when cells are exposed to physiological genomic stress such as aging, 
p16INK4a is expressed and induces immediate and irreversible cell cycle arrest that may 
ultimately lead to apoptosis (Beausejour et al. 2003). Thus, independent of HPV status, 
p16INK4a expression is sometimes observed in single cells that undergo modifications of 
their normal differentiation program due to aging or genomic stress (Wentzensen et al. 
2007; Tringler et al. 2004). 
  
 
Figure 2-8 Schematic diagram of the cellular proteins involved in G1-S phase transition 
and the interference of HPVE7. 
2.4.3.3 Ki-67 
The proliferation marker Ki-67 is a nuclear protein associated with cell proliferation. 
The Ki-67 antigen is visualized using monoclonal antibody MIB-1. Ki-67 is expressed 
during the active phases of the cell cycle G1, S, G2 and M, but absent among resting 
cells in G0. In normal cervical squamous epithelium the proliferation marker Ki-67 is 
confined to the parabasal cell layer. In intraepithelial lesions extended expression 
correlates with disordered maturation. As a pure proliferation marker, Ki-67 alone 
cannot discriminate HPV-mediated dysplasia from reactive cell proliferation in 
response to benign processes (Hwang et al. 2012), but it is used as an adjunct to 
morphological assessment in grading cervical dysplasia (Kruse et al. 2001; Baak et al. 
2005). Figure 2-7 illustrates different marker levels during progression of 
carcinogenesis as discussed above. 
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3 AIMS 
Because there has been an increase in the incidence of adenocarcinoma of the uterine 
cervix, especially among young women, and cytological screening for detection of this 
type of cancer is inadequate, other screening techniques are needed. The general aim of 
this thesis is to investigate the potential of different biomarkers as tools to reliably 
diagnose and predict prognosis for cervical adenocarcinoma.  
 
3.1 SPECIFIC AIMS 
3.1.1 Paper I 
The aim of this study was to evaluate the relationship between expression of the 
p16INK4a tumor suppressor and the Ki-67 proliferation marker (detected through MIB-1) 
in cervical adenocarcinoma and to correlate staining patterns with clinical parameters. 
3.1.2 Paper II 
The aim of this study was to evaluate whether the real-time NASBA-based PreTect 
HPV-Proofer assay (NorChip AS, Klokkarstua, Norway) can be used to detect the full-
length mRNA E6/E7-region of five HR-HPV types in paraffin-embedded tissue 
samples of cervical adenocarcinoma. We wanted to analyze whether the PreTect HPV-
Proofer is a more sensitive method for detection of adenocarcinoma of the cervix due to 
transforming HPV infection, than using the DNA test in paraffin-embedded material. 
 
3.1.3 Paper III   
The aim of this study was to evaluate immunohistochemical expression of LRIG 
proteins in cervical adenocarcinomas, and to investigate possible correlations between 
LRIG expression, patient survival and HPV status. 
 
3.1.4 Paper IV 
The aim of this study was to examine whether WIG-1 (p53 target gene) is a molecular 
marker for cervical carcinogenesis and to evaluate whether Wig-1 expression differs 
between HPV-positive and HPV-negative cervical cancers. We also investigated the 
correlation between WIG-1 expression and clinical outcome. 
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4 MATERIAL AND METHODS 
4.1 TUMOR MATERIAL 
All tumor cases were identified from the Swedish National Cancer Registry maintained 
by the National Board of Health and Welfare. This registry includes all cases of 
malignant tumors diagnosed histopathologically since 1959, with each tumor identified 
by a topographical and a histopathological code. All studies were approved by the 
Regional Ethics Review Board in Stockholm and all women provided written informed 
consent to participate in the studies, 
4.1.1 Paper I 
The study includes formaldehyde-fixed paraffin-embedded tumor tissue specimens 
from 101 primary cervical adenocarcinomas diagnosed and surgically treated at 
Karolinska University Hospital-Huddinge between 1992 and 2000. All tumor samples 
were collected, with informed consent and approval from the local ethics committees. 
The histopathological diagnoses were based on WHO criteria. In all, 101 tumors were 
classified as cervical adenocarcinomas and all lacked any squamous cell component. 
Eight adenocarcinomas showed only superficial proliferation in the mucosa with no 
obvious signs of infiltration into surrounding stroma. These tumors were regarded as 
“in situ adenocarcinomas” and the remaining 93 tumors as “infiltrating cervical 
adenocarcinomas”. Information concerning stage of differentiation was available for 89 
of the tumors, while information on clinical stage was available for 76 cases. All 
patients were retrospectively followed-up from time of diagnosis until January 2007 
and disease recurrence and survival data were recorded. 
4.1.2 Paper II 
The study includes formaldehyde-fixed paraffin-embedded tumor tissue specimens 
from 98 primary cervical adenocarcinomas taken from the previous material that were 
diagnosed and surgically treated at Karolinska University Hospital-Huddinge between 
1992 and 2000. Eight adenocarcinomas showed only superficial proliferation of the 
mucosa with no obvious signs of infiltration into surrounding stroma. These tumors 
were regarded as “in situ adenocarcinomas,” while the remaining 90 tumors were 
considered to be “infiltrating cervical adenocarcinomas.” All patients were 
retrospectively followed-up from time of diagnosis until January 2007 and disease 
recurrence and survival data were recorded. 
4.1.3 Paper III 
This study looked at a cohort of 86 patients with primary cervical adenocarcinoma 
treated at Karolinska University Hospital, Huddinge, between 1992 and 2000. The 
previous study included 101 patients, while the current study conducted 
immunohistochemical analyses for the expression of LRIG proteins in 86 patients, after 
15 patients were excluded due to an insufficient amount of material. 
All tumors were cervical adenocarcinomas and lacked any squamous cell component; 
79 were invasive, 4 were in situ and histopathological diagnosis could not be 
ascertained for the remaining 3 tumors. All patients were retrospectively followed up 
from time of diagnosis until January 2011 and survival data were recorded. 
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4.1.4 Paper IV 
For the first part of the study eight human cervical cancer cell lines Ca Ski, SiHa, C-4 I, 
C-33A, ME-180, HT-3, MS751 and SW756 and a osteosarcoma cell line Saos2 were 
purchased from the American Type Culture Collection, ATCC 
(http://www.lgcstandards-atcc.org).  
For the immunohistochemical portion of the study, biopsies were collected from 38 
patients who were diagnosed between 1989 and 2010 at the Department of Obstetrics 
and Gynecology, Karolinska University Hospital. Included were 13 cases of squamous 
cell carcinoma samples and 25 cases of invasive adenocarcinoma samples that had also 
been included in studies I-III. The biopsies were grouped according to morphological 
diagnosis and the histopathological diagnosis was based on WHO criteria. All patients 
were retrospectively followed up from time of diagnosis until January 2012. Clinical 
information on patients, including age at diagnosis, stages and survival data, was 
recorded. 
4.2 METHODS 
4.2.1 Sample preparation 
The tumor tissue was formalin-fixed and paraffin-embedded. Serial sections of 10µm 
were from each block. One section was stained with hematoxylin-eosin for histological 
evaluation, while the remainder was used for further investigation, depending on the 
study. Figure 4-1 gives an overview of material and methods applied in study I-III. 
4.2.2 HPV DNA testing 
Analyses were performed on DNA extracted from a 10-μm-thick section of paraffin 
blocks; the preceding section had been used for morphological diagnosis. A fragment 
of 150 bp was amplified from the L1 region using GP5+/GP6+ primers, PCR followed 
by SSCP typing,  or HPV-typed by direct DNA sequencing and comparison with 
known HPV sequences using the BLAST algorithm (www.ncbi.nlm.nih.gov/BLAST). 
In paper II for cases previously tested as HPV-negative (28), the Linear Array HPV 
Genotyping Test (LA) was carried out.  
4.2.2.1 HPV DNA extraction and detection with Linear Array 
Paraffin-embedded archival biopsies were de-waxed with xylene-ethanol and  DNA 
was extracted using a MagNA Pure LC Robot in accordance with the procedure 
outlined in the manufacturer’s manual (Roche Diagnostics, Basel, Switzerland). HPV-
DNA detection and genotyping were carried out using the Linear Array (LA) HPV 
Genotyping Test outlined in the manufacturer’s manual (Roche Diagnostics, Basel, 
Switzerland), which is capable of detecting 37 HPV types divided into three "risk 
categories" according to Muñoz and co-workers (Muñoz et al. 2003).  
4.2.3 E6/E7 mRNA analysis (Paper II)  
Paraffin-embedded tissue blocks were sliced with a microtome blade into five 10-μm 
sections and transferred to 1.5 ml RNase-free vials and stored at 4ºC. The microtome 
and forceps were cleaned with 70% ethanol twice between each sampling to prevent 
contamination between blocks. Sections for RNA analysis were incubated in two 
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consecutive baths of xylene for 10 minutes each before centrifugation for 5 minutes at 
2500 rpm, followed by two consecutive baths in 100% ethanol, 10 minutes each. After 
final centrifugation for 5 minutes at 2500 rpm, the pellets were dried at 55ºC for 2-4 
hours and treated for at least 3 hours with 100 μl 0.5 mg/ml proteinase K (Invitrogen, 
Carlsbad, USA, 20 mg/ml) in RNase-free 1x Tris-HCl (Sigma Aldrich, St. Louis, USA) 
at 55˚C until digestion was complete. Finally, 900 μl lysis buffer (Nuclisens, 
bioMérieux, Marcy l'Etoile, France) was added to each tube before extraction using the 
NucliSens manual extraction kit (bioMerieux, Marcy l'Etoile, France). Extracts were 
stored at -80ºC. 
Full-length mRNA from HPV types 16, 18, 31, 33, and 45 were detected using the real-
time NASBA-based assay (PreTect HPV-Proofer, NorChip AS, Klokkarstua, Norway), 
according to manufacturer instructions. 
To avoid false negatives due to degradation of mRNA, primers and probes against 
human U1A mRNA are included in the HPV-Proofer kit for performance and integrity 
control. However, the U1A control was found to be suboptimal for integrity control in 
paraffin-embedded tissue due to modified or fragmented nucleic acids, and was 
therefore replaced by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The 
amplicon defined by the GAPDH primers was adjusted in size to better match the HPV 
amplicons.  
4.2.4 Immunohistochemistry (Paper I; III; IV) 
4.2.4.1 Immunohistochemistry for p16INK4a and Ki-67  
Immunohistochemical staining was performed with the CINtec®. Histology Kit (Code 
No. K5336, Dako Cytomation, Glostrup, Denmark) following the manufacturer's 
recommendations and using the Dako Autostainer. This kit contains Tris EDTA buffer 
(x10) pH 9.0 intended for epitope retrieval. A Coplin jar filled with the diluted epitope 
retrieval buffer (1:10 distilled water) was placed in a water bath and heated to 95-99˚C. 
Deparaffinized sections were then incubated for 10 minutes while maintaining a 
temperature of 95-99˚C. Jars with slides were removed from the water bath and left to 
cool at room temperature for 20 minutes, followed by washing for 5 minutes in Wash 
Buffer (Code No. S3006, Dako Cytomation) diluted 1:10 with distilled water. The 
automated procedure began with 1x rinse (1x rinse equals 4 min) in wash buffer 
diluted. 
1:10 with distilled water [Wash Buffer (x10), Code No. S3006, Dako Cytomation]. 
Endogenous peroxidase activity was blocked by incubating slides for 5 minutes in 
Peroxidase-Blocking Solution (Dako REAL™, Code No. S2023, Dako Cytomation). 
Slides were rinsed 1x, after which 200 μl of the primary antibody to the p16INK4a 
protein clone E6H4 was dropped onto each slide, followed by incubation for 30 
minutes. Slides were rinsed once. Reaction products were visualized by incubating 
slides for 30 minutes with the Visualization Reagent (a horseradish peroxidase/goat 
anti-mouse immunoglobulin-labeled dextran polymer) and, after 2 rinses, incubating 
for 10 minutes in a 1:40 solution of DAB chromogen (3.3'-diaminobenzidine) in DAB 
Buffered Substrate, also from the CINtec® Histology Kit. Slides were then washed in 
distilled water for 1 minute and counterstained for 2 minutes in Harris Hematoxylin 
solution diluted 1:2 with distilled water. After 2 minutes of washing in water, slides 
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were then dehydrated in ethanol to xylene and mounted in a water-free permanent 
mounting medium with mounting glass. Tissue sections containing cervical cancer 
were used as positive controls for p16INK4a, while negative controls consisted of 
incubated doublet slides in the Negative Control Reagent contained in the kit, instead of 
primary antibodies. Immune staining was considered positive for p16INK4a  when the 
nuclei were clearly stained. In addition, cells with a distinct cytoplasmic 
immunoreaction were scored as positive. Scoring of the immunohistochemistry results 
was performed on the basis of both staining intensity and percentage of 
immunoreactive epithelial cells. Scoring criteria for p16INK4a, expressed as percentages 
(%) were: negative  =no expression; <20 =weak staining (±); 20-30 =weak to moderate 
staining (+); 31-50 =moderate to strong staining (++); >50 =strong staining (+++). 
Scores of +, ++ and +++ were considered positive for p16INK4a. 
To detect the Ki-67 antigen we used monoclonal mouse antibody (clone MIB-1), (Code 
No. M7240, Dako). The sections were deparaffinized, rehydrated, and microwaved in 
target retrieval solution diluted 1:10 with distilled water (Dako REAL Target Retrieval 
Solution (x10) Code No. S2023, Dako Cytomation) for 2x5 minutes at 500 W. 
Thereafter slides were loaded on the Autostainer according to procedure and run 
together with the p16INK4a slides as described above. Ki-67 positivity was scored on a 1-
3 scale in a manner similar to p16, but only with respect to both nuclear staining and 
attention to heterogeneity in distribution. 
4.2.4.2 Immunohistochemistry for the LRIG proteins 
Immunohistochemical staining of LRIG1, LRIG2 and LRIG3 was carried out using 
polyclonal rabbit antibodies against the cytosolic tails of the proteins. Tissue sections 
containing squamous cervical cancer were used as positive controls, and appropriate 
negative controls were always included. A senior pathologist blinded to all clinical 
data, evaluated the immune staining. Immunohistochemistry results were scored based 
on both staining intensity and percentage of immunoreactive epithelial cells. The 
percentage of positive cells was based on a 5-grade semi-quantitative scale: 0= no 
expression; 1= >0 and <24% positive cells, 2= 25-49% positive cells, 3= 50-74% 
positive cells, 4= >75% positive cells. Intensity of staining was evaluated on a four-
grade semi-quantitative scale: 0= no staining; 1= weak, 2= moderate, and 3= intense. 
4.2.4.3 Immunohistochemistry for Wig-1 
For assessment of Wig-1 a polyclonal rabbit antibody anti- Wig-1 from Genetex was 
used after deparaffinization and the common pretreatment, including incubation with 
normal goat serum (DAKO) to block nonspecific staining. Sections were first incubated 
with primary antibody against Wig-1 (1:400 in 1% BSA) at 4°C overnight, and 
subsequently with secondary antibody (Goat anti-rabbit from DAKO) and finally with 
ABComplex HRP (DAKO) to visualize reaction products. Slides were mounted after 
counterstaining with hematoxylin. Scoring of IHC results was performed on the basis 
of staining intensity and intracellular distribution (nuclear vs. cytoplasmic). Staining 
intensity was evaluated on a four-grade semi-quantitative scale: 0 (no staining), 1 
(weak), 2 (moderate), and 3 (strong). 
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Figure 4-1 Flowchart illustrating the design of study I- III 
4.2.5 Cell lines 
The eight cervical cancer lines Ca Ski, ME-180, MS751, SiHa, SW 756, C-4I, C-33A, 
and HT-3 were examined for structural and numerical alteration in the 3q region by 
SKY and CGH, respectively. Possible copy number alterations of the WIG-1 gene were 
assessed by Southern blot and dual color FISH. mRNA expression was examined by 
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Northern (qualitative) and RT-PCR (quantitative). Finally, Wig-1 protein expression 
was evaluated by Western Blot.  
4.2.6 Statistical analysis 
The Statistical Program for Social Sciences (SPSS) was used for statistical analysis and 
a significance level of p< 0,05 was applied. In Paper I the impact of biomarkers on 
survival was evaluated by Cox regression analysis and the relation between two 
variables was examined using ANOVA. In paper II Cox regression analysis was 
applied to evaluate the difference in survival between HPV mRNA positive and 
negative cases. Chi-2 or Fisher’s exact test were used for evaluation of ordinal 
variables. The impact of HPV status and expression of the LRIG proteins on survival 
was described in a Kaplan-Meier graph and survival in different groups was compared 
using the log rank test. Cox regression was applied for multivariate analysis of different 
molecular markers. In paper IV ANOVA was performed to examine the correlation 
between WIG-staining and clinical parameters, as well as HPV status. Survival 
distribution in different groups was tested with the Log rank test and described in a 
Kaplan Meier graph. 
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5 RESULTS AND DISCUSSION  
5.1 PAPER I 
The objective of this study was to evaluate expression of the p16INK4a tumor suppressor 
gene and the proliferation antigen Ki-67 in cervical adenocarcinoma. We sought to 
evaluate the relationship between the two markers and clinical parameters such as age, 
stage, grade and survival. 
P16INK4a expression in relation to histology: 86% of tumors stained for p16INK4a. 
Surprisingly, the proportion of p16INK4a staining decreased with lower tumor grade 
(95% in well-differentiated tumors, 91% in moderate and 41% in poorly differentiated 
tumors). Similarly, a significant negative correlation was found between p16INK4a 
staining intensity and histological grade (p=0.001); we found that highly differentiated 
tumors stain more strongly than poorly differentiated tumors. No correlation was found 
between p16INK4a staining intensity or proportion of stained samples and tumor stage. 
No correlation was found between p16INK4a staining and either age or survival. 
 
 
Figure 5-1 Different scores of p16 expression in samples with various grade of 
differentiation of cervical adenocarcinoma. Frequency of different scores of p16 antigen 
expression in all samples, distributed over the four grades, as shown in 97 cases. Vertical 
hatched bars, AIS (6 cases); crosshatched bars, highly differentiated tumors (41 cases); 
chess hatched bars, moderately differentiated tumors (32 cases); and punctuated bars, 5 
cases where histology showed poor differentiation. 
 
HPV infection was strongly correlated with higher p16INK4a staining (p=0.00). None of 
the HPV-positive tumors was p16INK4a-negative and 40% of the HPV-negative tumors 
were also negative for p16INK4a expression. The remaining 60% stained with varying 
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intensity. No single HPV type was found to be more strongly associated with p16INK4a 
expression than any other type.   
The p16INK4a tumor suppressor gene is inactivated in many carcinomas, but in cervical 
carcinoma it is often overexpressed, both in the nucleus and the cytoplasm (Saqi et al. 
2002). The majority of cervical cancer is caused by HR-HPV infection. Overexpression 
of p16INK4a in these tumors is thought to be the result of functional inactivation of the 
Rb tumor suppressor protein by the E6 and E7 viral oncoproteins (Klaes et al. 2001). 
p16INK4a transcription is induced by transcription factor E2F, which is released from Rb 
after Rb binding to the HR-HPV E7 protein (Khleif et al.1996).  Release of E2F 
activates transcription of p16INK4a , which accumulates to high levels in the cell. It has 
been shown that evaluation of p16INK4a immunostaining allows identification of 
preinvasive and invasive cervical squamous lesions in biopsies, while reducing both 
false negative and false positive readings (Klaes et al. 2001). Expression of p16INK4a 
has been discussed as a potential predictor of rapid progression, as seen in a 
longitudinal study (Wang et al. 2004) and its expression may suggest the presence of 
transformed cells, even if the lesions appear morphologically normal. However, the 
specificity of the method has been debated since it has previously been shown to have 
limited application in cervical glandular lesions (Murphy et al. 2004). Positively 
staining p16INK4a samples in the setting of relatively few Ki-67 expressing cells has 
been seen in squamous metaplasia (Nielsen et al. 1999). Our earlier study showed a 
positive correlation between grade of CIN and expression of p16INK4a in squamous cell 
lesions (Andersson et al. 2006c). p16INK4a has also been tested as a marker for 
persistence of HPV infection, a predictor of progression to cancer, and has been found 
to correlate with histological grade (Branca et al. 2004; Negri et al. 2004). The majority 
of the studies did show elevated p16INK4a levels in HR-HPV positive cervical cancer, 
although the studies mainly addressed squamous cell cancer.  
In our material, p16INK4a staining correlated with degree of histological differentiation, 
showing a lower proportion of staining in poorly differentiated tumors. Some studies 
evaluated expression of p16INK4a in adenocarcinoma. Missaoui et al. found p16INK4a 
expression in all such cases, although the authors did not specify grade of 
differentiation (Missaoui et al. 2006). Ishikawa et al. found no correlation between 
p16INK4a expression and histological subtype of adenocarcinoma, age, stage or 
recurrence (Ishikawa et al. 2003).  
We suggest that the reason for lower p16INK4a expression in less differentiated tumors is 
that highly differentiated tumors may still have the capacity to express the p16INK4a 
tumor suppressor owing to the oncogenic activity of HR-HPV E7, whereas poorly 
differentiated tumors may have lost this capacity.  
Our finding that all HPV-positive adenocarcinomas stained for p16INK4a is consistent 
with results from other groups (Missaoui et al. 2006). The etiological role of HR-HPV 
in cervical adenocarcinoma is not completely understood. In our material, we found 
that 64% of tumors were HR-HPV positive. Impaired gene expression probably 
contributes to carcinogenesis in some adenocarcinomas, especially in HPV-negative 
cases. In our material, no detectable p16INK4a overexpression was found in 40% of 
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HPV-negative tumors. Thus loss of functional p16INK4a may cause uncontrolled 
proliferation, or even possibly result from it.     
The fact that 60% of HPV-negative tumors in our sample showed overexpression of 
p16INK4a signals that HPV independent mechanisms can also lead to overexpression of 
p16INK4a.  Alternatively, this finding could be due to undetected past or current HPV 
infection.  
MIB-1 levels were used to reflect Ki-67 expression and, as expected, histological grade 
correlated strongly with Ki-67 expression, showing both increased intensity and higher 
fraction of Ki-67 staining with higher tumor grade. All poorly differentiated tumors 
stained for Ki-67. The correlation between staining intensity and tumor grade was 
significant (p=0.004). Furthermore, higher MIB-1 levels were significantly associated 
with higher tumor stage at diagnosis (p=0.038). Higher MIB-1 levels as a marker for 
Ki-67 expression showed a significant correlation with poorer outcome (p=0.004) after 
adjusting for age. 
HPV infection correlated significantly with better survival, but after adjusting for age 
this correlation was no longer significant. 
 
Figure 5-2 Different scores of MIB-1 expression in samples with various grade of 
differentiation of cervical adenocarcinoma. Ninety-nine cervical adenocarcinomas were 
evaluated for the expression of MIB-1 antigen. Vertical hatched bars, AIS (5 cases); 
crosshatched bars, highly differentiated tumors (40 cases); chess hatched bars, 
moderately (35 cases); and punctuated bars, 13 cases with poor differentiation histology. 
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Some studies have indicated the potential value of immunostaining for Ki-67 to 
distinguish endocervical neoplasia from benign endocervical lesions. Cina et al. 
reported that Ki-67 staining was negligible or low in normal endocervical tissue (Cina 
et al. 1999). In our study we found that the MIB-1-positive proportion of samples and 
labeling intensity both correlated with cancer stage and grade; higher levels of MIB-1 
were associated with higher stage at diagnosis and more poorly differentiated tumors. 
Higher levels of MIB-1, representing the Ki-67 proliferation antigen, were significantly 
associated with poorer outcomes in our patients. This result is consistent with previous 
studies of squamous cell carcinomas, suggesting that higher MIB-1 levels are powerful 
predictors of shorter survival (Ho et al. 2000). However, other investigations found that 
MIB-1 expression had no clinical utility for predicting long-term disease-free survival 
(Avall-Lundqvist et al. 1997; Graflund et al. 2002). 
Our study found a significant positive correlation between p16INK4a and Ki-67 staining. 
The interaction between p16INK4a and Ki-67, the so-called dual-stain approach, has been 
increasingly investigated in recent years. Under physiological conditions, simultaneous 
expression of the p16INK4a tumor suppressor and the Ki-67 proliferation marker should 
exclude each other. Thus, the combined detection of both markers should represent 
deregulation of cell cycle control, resulting from infection with oncogenic HPV. 
Simultaneous p16INK4a/Ki-67 expression has been reported to increase with severity of 
lesion (Wentzensen et al. 2012). Its diagnostic potential has been shown with respect to 
effective triage of ASCUS and LSIL (Schmidt et al. 2011; Petry et al. 2011) and its 
sensitivity to detect CIN2+. 
In summary, we found that a lower proportion of poorly differentiated tumors stain for 
p16INK4a and do so with less intensity than do well-differentiated lesions; all HPV-
positive tumors demonstrated p16INK4a staining, but 60% of HPV-negative tumors also 
stained for p16INK4a. Moreover, we found a significant correlation between staining for 
Ki-67 and histological grade, in regard to both staining intensity and proportion of 
samples that stain. Poorer outcome was significantly related to higher Ki-67 staining. 
5.2 PAPER II 
The aim of our study was to compare DNA-based and mRNA-based methods with 
respect to detection of HR-HPV in paraffin-embedded samples of cervical 
adenocarcinoma. Since the PreTect HPV-Proofer always detects full-length E6/E7 
mRNA, a positive finding should strongly correlate with integrated HPV, loss of HPV 
replication, and stabilized E6/E7 full-length mRNA expression. Stabilized E6/E7 full-
length mRNA resulting from integration of HPV correlates very well with high, stable 
expression of full-length E6 proteins. HPV mRNA testing demonstrated HPV in 64% 
of samples, while HR-HPV DNA testing with GP5+/GP6+ PCR and SSCP or direct 
sequencing revealed HPV in 62% of samples. Another eight samples turned HR-HPV 
positive after retesting with the reverse line blot method using Linear Array (Roche).  
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Figure 5-3 Detection of different HPV types with DNA and mRNA methods. 
Previous studies using PCR techniques to detect HPV DNA on formalin-fixed, 
paraffin-embedded biopsy specimens of cervical adenocarcinomas, reported HPV 
positivity at rates ranging from 32% to 85% (Duggan et al. 1995; Clifford et al. 2006). 
Prevalence of HR-HPV may be higher when examining fresh-frozen tumor tissues 
because of alterations in the DNA sequence caused by formalin fixation and storage in 
paraffin (Karlsen et al. 1994; Williams et al. 1999; Tang et al. 2006). Successful  
extraction of intact mRNA from paraffin-embedded samples was confirmed using 
GAPDH control.  
Differences in sensitivity may be due to use of different DNA/RNA extraction 
methods, primers, and consensus and/or HPV type-specific primers, as well as to 
differences in preparation, fixation, and processing of sample tissue. However, the main 
reason for reduced sensitivity may be the lack of control for presence of cancer tissue in 
all collected sections. In this study, it was not possible to include histological evaluation 
of tissue samples before and after the tissue was used for RNA/DNA extraction. 
Another factor that may reduce efficiency of HPV detection is loss of portions of the 
viral genome during integration. Integration of HPV DNA may result in deletion of the 
viral genome containing the sequences targeted by the PCR reaction. A higher 
proportion of DNA integration in glandular lesions compared with squamous lesions 
may result in a lower proportion of detectable episomal HPV genome and thereby lead 
to significant underestimation of HPV DNA in cervical adenocarcinomas (Park et al. 
1997; Chung et al. 2008).  
In 8 (8%) cases, the results of the mRNA-based and DNA-based methods differed 
regarding HPV type. An earlier study on cervical squamous cell cancer that compares 
the mRNA and DNA methods describes type mismatch in only 2% of cases (Kraus et 
al. 2006). We retested 4 of these cases using Linear Array and found type consistency 
with mRNA in all 4 cases. Results regarding HR-HPV presence or absence obtained 
through DNA and mRNA testing were consistent in 87% of samples.  
* Includes HPV DNA 31/33 
and an unknown case;   HPV 
mRNA 16/18 and HPV16/31 
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Both assays revealed ~70% positive findings for HPV when targeting HPV 16 and 18 
alone. HPV types 16, 18, 31, and 45 accounted for 99% of all HPV types within our 
group of 77 HPV-positive cases. 
HPV type in cocktail # Types #TP #FN FP± #TN Sensitivity 
0 0 0 78* 0 20 0% 
HPV 16 1 28 50 0 20 35.9% 
HPV 16-18 2 53 25 0 20 67.9% 
HPV 16-18-45 3 59 19 0 20 75.6% 
HPV 16-18-45-31 4 60 18 0 20 76.9% 
HPV 16-18-45-31-33 5 60 18 0 20 76.9% 
*One case with unknown HPV-type, thereby giving total positives 60 (TP60) instead of 61 (TP61) 
± Specificity was overall 100%, because we included only cases with adenocarcinoma. 
Table 5-1 Number of TP, FN, TN detected in HPV positives (by any method) in cervical 
adenocarcinoma using SSCP and direct sequencing 
 
± Specificity was overall 100%, because we included only cases with adenocarcinoma. 
Table 5-2 Number of TP, FN, TN detected in HPV positives (by any method) in cervical  
adenocarcinoma using PreTect  HPV-Proofer 
In summary, our data indicate that mRNA HPV testing is at least as sensitive as HPV 
DNA testing to identify women with cervical adenocarcinoma and that mRNA 
extracted from paraffin-embedded tissue sections could be used for further 
investigations. Since most adenocarcinomas are HPV-positive, it is possible that 
mRNA testing will have a stronger impact on prevention of adenocarcinoma than 
cytological screening, especially in young females. Thus, E6/E7 oncogene expression 
analysis of precursor lesions (i.e., adenocarcinoma in situ and glandular dysplasia) will 
be the next step to verify the potential of E6/E7 expression as a molecular marker for 
early detection and progression to invasive disease. In contrast to cytology, detection of 
E6/E7 HPV mRNA is an objective molecular marker, and may allow diagnosis of 
cervical adenocarcinoma at an earlier stage in the natural history of the disease. The 
ability to detect almost all HPV-related adenocarcinomas, including the limited HPV 
types covered by the PreTect HPV-Proofer assay, is a new discovery that underscores 
the potential of this test for adenocarcinoma screening. 
5.3 PAPER III 
Our main finding was a significant correlation between survival and expression of 
LRIG1 and LRIG3. Survival was significantly better among patients with tumor 
samples that exhibited moderate or intense staining for LRIG1 than among those with 
HPV type in cocktail # Types #TP #FN #FP ± #TN Sensitivity 
0 0 0 78 0 20 0.0% 
RNA16 1 32 46 0 20 41.0%  
RNA 16-18 2 53 25 0 20 67.9%  
RNA 16-18-45 3 63 15 0 20 80.8%  
RNA 16-18-45-31 4 63 15 0 20 80.8%  
RNA 16-18-45-31-33 5 63 15 0 20 80.8%  
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tumors showing no or mild intensity of LRIG1 staining (p=0.003). Significantly better 
survival was also observed in patients with tumors where 50% or more of the cells 
stained for LRIG3 compared with patients whose tumors showed a lower fraction of 
LRIG3 staining (p=0.004). Multivariate regression analysis showed that the LRIG3-
positive fraction was the only independent parameter exerting a statistically significant 
influence on survival, apart from age.    
IHC analysis of LRIG proteins showed a balanced distribution of staining intensity for 
LRIG1 and LRIG2, but not for LRIG3 where 89.4% of tumor samples showed weak or 
no staining. The majority of tumor samples showed staining in >50% of cells: 64% for 
LRIG1, 74.4% for LRIG2, 54% for LRIG3. Intracellular distribution varies for LRIG 
proteins: LRIG1 was only found in cytoplasm, LRIG2 was seen in the cytoplasm and 
nucleus, while LRIG3 was mainly detected in the nucleus. 
 
A LRIG staining intensity 
 No staining 
0 
Weak 
1+ 
Moderate 
2+ 
Intense 
3+ 
LRIG1 11 (12.9%) 18 (21.2%) 26 (30.6%) 30 (35.3%) 
LRIG2 5 (5.9%) 19 (22.4%) 34 (40.0%) 28 (31.8%) 
LRIG3 17 (20.0%) 59 (69.4%) 8 (9.4%) 1 (1.2%) 
 
B 
 
Fraction of LRIG positive cells 
 0 
 
>0 - 24% 
1+ 
25 - 49% 
2+ 
50 - 75% 
3+ 
>75% 
4+ 
LRIG1 11 (12.8%) 4 (4.7%) 16 (18.6%) 25 (29.1%) 30 (34.9%) 
LRIG2 5 (5.8%) 3 (3.5%) 14 (16.3%) 8 (9.3%) 56 (65.1%) 
LRIG3 17 (20.0%) 11 (12.9%) 11 (12.9%) 11 (12.9%) 35 (41.1%) 
 
Table 5-3 Staining intensity (A) and fraction of positive cells (B) of the LRIG 
immunohistochemical analysis. 
In this study, both higher intensity of LRIG1 staining and higher proportion of stained 
cells in the tumor were associated with improved patient survival. A correlation has 
been reported between higher expression in the tumor and better patient prognosis in 
breast cancer (Krig et al. 2011), cutaneous squamous cell carcinoma (Tanemura et al. 
2005) and early stage invasive squamous cervical cancer (Lindström et al. 2008). 
Moreover, increasing grade of CIN is associated with increasing LRIG1 expression 
(Lindström et al. 2011). These data suggest that LRIG1 is involved in both 
precancerous and invasive squamous cervical lesions. Our material showed that LRIG1 
also functions as a prognostic marker for cervical adenocarcinoma. An earlier study 
evaluated the prognostic impact of LRIG1 on cervical cancers, including both 
squamous cell and adenocarcinoma, in which no correlation with survival was found in 
the adenocarcinoma portion, possibly due to the limited sample size of 36 patients 
(Hedman et al. 2010). The finding that prognosis is improved by the presence of higher 
LRIG1 expression in both adenocarcinoma and squamous cell carcinoma of the cervix 
suggests an important role for this marker in the disease.  
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Figure 5-4 Correlation between LRIG1 staining intensity (A) and fraction of LRIG3 
staining cells (B) and survival. The 4 (A) or 5 (B) groups were dichotomized using the 
median as a cut-off to generate two groups of equal size. 
 
In cervical SCC, LRIG2 expression has been reported to correlate with worse survival 
(Hedman et al. 2010). In our material no such correlation between LRIG2 expression 
and survival or other clinical parameters was found for cervical adenocarcinoma. Thus, 
LRIG2 might be more important as a possible marker of prognosis in cervical SCC and 
other cancer types. 
Staining for LRIG3 has been evaluated in oligodendroglioma and in astrocytic tumors. 
Perinuclear staining of LRIG3 in astrocytic tumors correlated with better survival (Guo 
et al. 2006). This is consistent with the findings in the present study where LRIG3 is 
linked to better survival. LRIG3 may have a tumor suppressive function similar to that 
of LRIG1. However, recent experimental results have shown that LRIG1 and LRIG 3 
interact with ErbB2, where the latter exerts an opposite effect on the receptor (Abreira 
et al. 2010, Rafidi et al. 2013). 
A significant correlation was seen between HPV status and staining intensity for 
LRIG1 (p=0.001) and LRIG3 (p=0.004), with higher staining intensity in HPV-positive 
cases. No significant correlation was found between LRIG expression and stage or 
histological findings. HPV positivity was also identified as a significant prognostic 
factor (p<0.001). 
Whether or not the positive correlation between HPV status and staining intensity of 
LRIG1 and LRIG3 is relevant to prognosis remains to be elucidated. Nevertheless, 
LRIG3 has been shown to be an independent prognostic factor after multivariate 
analysis. For other HPV-related cancers, such as cancer of the tonsils and base of the 
tongue, the existence of two different tumor types with different prognosis, depending 
on HPV status, has been suggested (Attner et al. 2011, Hammarstedt et al. 2006). Our 
results suggest differences regarding prognosis between HPV-positive and HPV-
negative cervical adenocarcinomas, at least insofar as LRIG expression relates to 
patient survival. 
Thus, analysis of LRIG expression in precursor lesions (i.e., adenocarcinoma in situ 
and glandular dysplasia) will be important to determine the potential of LRIG proteins 
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as molecular markers for early detection and progression to invasive disease. LRIG 
immunoreactivity is of prognostic importance in cervical adenocarcinoma and 
correlates with HPV status. Therefore, LRIG proteins may be important determinants 
of cervical adenocarcinoma progression, which justifies further study of their 
diagnostic and prognostic potential in this disease. 
5.4 PAPER IV 
WIG-1 is amplified and/or overexpressed in many human tumors, indicating an 
oncogenic function (Varmeh-Ziaie et al. 2001). WIG-1 has been mapped to 
chromosome 3q26.3, a region that shows frequent copy number gain in various human 
tumors (Hellborg et al. 2001). Gain of chromosome 3q occurs during progression from 
cervical carcinoma in situ to advanced invasive cancer (Heselmeyer et al. 1996). These 
findings suggest that in cervical cancer WIG-1 is associated with gain of 3q. We 
therefore examined Wig-1 expression in cervical carcinoma cell lines and assessed 
Wig-1 expression in biopsies containing samples of cervical carcinoma. 
5.4.1 Cell line studies 
We first assessed structural and numerical alterations of the WIG-1 locus in cervical 
carcinoma cell lines by SKY and CGH analyses, which showed that WIG-1 is not a 
primary target for chromosome 3 alterations in these cells. We found single structural 
chromosome 3 abnormalities by SKY in six cells, but in no case did the breakpoint 
involve the 3q26.32 region where WIG-1 is located. All eight lines studied by CGH 
exhibited copy number variations of chromosome 3.  
We then studied the WIG-1 locus for possible copy number variations. Using Southern 
analysis, WIG-1 was compared with a control marker from the short arm of the same 
chromosome (3p23), which showed modest gain of WIG-1 in MS751 and ME-180 
cells. High copy-number amplification of WIG-1 was excluded by dual color FISH 
using WIG-1 and D3Z1 probes. 
WIG-1 is located telomeric to the commonly amplified 3q23-24 interval in Me180 and 
SiHa cells, and centromeric to the amplified 3q27-ter interval in ME-180 cells. 
Moreover, the 3q amplifications detected by CGH were not accompanied by WIG-1 
locus amplifications as determined by Southern blotting or FISH. Thus, we conclude 
that WIG-1 is not the critical gene that drives 3q gain in cervical cancer. 
We assessed WIG-1 mRNA and protein expression in all cell lines by Northern and 
Western blotting. HT-3, C-33A and Saos-2 cells showed strong WIG-1 mRNA 
expression, while Ca Ski, ME-180, SiHa and SW756 showed weaker but clearly 
detectable expression. Western blotting showed Wig-1 protein expression in all cell 
lines. However, no associations were found between WIG-1 expression and copy 
number variations at the DNA level. WIG-1 mRNA expression, as assessed by 
quantitative RT-PCR, was higher in the two HPV-negative cervical carcinoma lines 
(C33-A, HT-3) than in the HPV-positive cell lines. We found no association between 
WIG-1 protein expression and HPV infection in cell lines. 
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Cell line HPV Chromosome Chromosome 3 aberrations 
Name Infection content by SKY by CGH**** 
Ca Ski HPV-16 (3n) 64-74 der(3)t(3;12)(p22;q24)  +3p12-qter(q23-q26) 
ME-180 HPV-68** (2n) 54-57 i(3)(q10) +3q(q27-qter) 
MS751 HPV positive*** (2n-3n) 37-75 der(3)t(3;8)(p11;q11) -3pter-p11, +3q24-q26 
SiHa HPV-16 (3n) 65-71 der(X)t(X;?3)(p11;?) +3p25-q26(q23-q24) 
SW756 HPV-18 (2n) 37-45 None +3q26 
C-4I HPV-18 (2n) 35-45 None +3q24-q26 
C-33A Negative (2n) 42-47 None +3p21, +3q26 
HT-3 Negative (3n) 57-59 der(3)t(3;12)(p11;q11) -3p, +3q26-q27 
Saos2* Negative (2n-4n) 52-99 dup(3)(q12q29); dic(3;19)(?;q13.3); +3q 
    der(X)t(X;1;3)(X?->cen->X?::1?->1?::3?->3?)  
*Saos2 is a osteosarcoma cell line 
**According to ATCC it contains HPV-39 
*** HPV type could not be determined by direct DNA sequencing of PCR products 
**** Bold in parenthesis indicates amplification within the gained interval 
 
Table 5-4 HPV status and chromosome 3 aberrations in the cervical cancer cell lines. 
 
 
 WIG-1 copy number by WIG-1 / Wig-1 expression TP53 / p53 status** 
Cell FISH Southern  WIG-1 by Wig-1  
Line WIG-1 vs. D3Z1 WIG-1 vs. 3p23 Northern qRT-PCR* by Western TP53 sequence p53 expression 
HPV positive        
Ca Ski no amplification n. d. + 3.07 positive wild-type very low / absent 
ME-180 no amplification gain + 4.91 positive wild-type very low / absent 
MS751 no amplification gain - 5.95 positive wild-type absent 
SiHa no amplification no gain + 2.75 positive wild-type very low / absent 
SW756 no amplification no gain + 3.13 positive n. a. n. a. 
C-4I no amplification no gain n. d. 4.67 positive wild-type very low / absent 
HPV negative        
C-33A no amplification no gain ++ 5.79 positive mutated (p.Arg273Cys) high but inactive 
HT-3 no amplification n. d. ++ 5.47 positive mutated (p.Gly245Val) high but inactive 
Saos2 n. d. no gain ++ 11.74 positive homozygously deleted absent 
- = negative; + = detectable to moderate expression; ++ = strong expression; n.d. = not determined; n.a. = not available; 
* Given in arbitrary units as compared to fibroblasts (1.0) 
** Reiss et al., 1992; Yaginuma et al., 1991; Srivastava et al., 1992; Scheffner et al., 1991; Masuda et al., 1987 
 
Table 5-5 Copy number and expression data of WIG-1 / Wig-1 data in relation to HPV 
infection and TP53 / p53 status. 
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5.4.2 Cervical carcinoma tissue studies 
The next step was to evaluate Wig-1 protein expression by immunohistochemistry in 
tissue samples of cervical carcinoma. All 38 cervical cancer cases in this study stained 
positive for Wig-1, mainly in cell nuclei. None of the 38 cases were Wig-1 negative; 
40% showed moderate and 55% showed strong staining. Cytoplasmic Wig-1 staining 
intensity was relatively low compared with nuclear staining in most tumors; 58% of 
tumors showed negative cytoplasmic Wig-1 staining, while 42% showed weak staining. 
We observed two distinct Wig-1 immunostaining patterns: A) high nuclear staining 
with negative cytoplasmic staining and B) low nuclear staining with positive 
cytoplasmic staining. Of the 38 tumors, 8 showed pattern A and 14 showed pattern B. 
Normal tissue adjacent to the tumors showed moderate nuclear Wig-1 staining. 
Interestingly, these staining patterns showed a significant correlation with HPV status. 
Moreover, nuclear Wig-1 staining intensity was significantly associated with tumor 
type (p < 0.0001); ADC samples showed higher nuclear Wig-1 expression than did 
SCC samples. 
We observed a possible correlation between Wig-1 expression and HPV status in these 
cervical carcinomas. HPV DNA is known to be almost invariably present in SCC 
(Walboomers et al.1999, Bosch et al. 2002}; however, our tumor material included 4 
HPV-negative SCC cases. We first investigated whether Wig-1 expression differed 
between HPV-positive and HPV-negative adenocarcinomas (ADC). We found a 
statistically significant difference in nuclear Wig-1 staining intensity between HPV-
positive and HPV-negative ADC cases (p = 0.049). After including all SCC cases, 
nuclear Wig-1 staining intensity remained significantly different between the HPV-
positive and HPV-negative cervical tumors (p = 0.002).  
We previously found that 70% of ADC cases were HPV DNA positive by PCR and 
direct HPV DNA sequencing (Andersson et al.2003). Thus, factors other than HPV are 
likely to play a role in the development of cervical ADC. The higher nuclear Wig-1 
expression in the HPV-negative tumors suggests that elevated expression of Wig-1 
might play a role in cervical carcinogenesis in the absence of HPV infection. 
Furthermore, we found a trend indicating that moderate nuclear Wig-1 expression and 
positive cytoplasmic Wig-1 expression are associated with better overall survival (p= 
0.126 and p= 0.110, respectively). In agreement with previous studies, patients with 
HPV-positive tumors had better survival (p= 0.066) than those with HPV negative 
tumors (though this relationship was not adjusted for age). 
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Figure 5-5 Survival curve to compare overall survival rates of patients between different 
nuclear (A) and cytoplasmatic (B) WIG-1 staining intensities of tumors by Kaplan-Meier 
analysis. Cases no. and Log Rank P values are indicated. 
 
We then examined survival for the subgroup of patients who had moderate nuclear and 
positive cytoplasmic Wig-1 expression in their tumors. We found that this subgroup of 
patients had a significantly better prognosis than patients with moderate nuclear Wig-1 
staining and negative cytoplasmic staining (p = 0.042). Since we observed higher 
nuclear Wig-1 expression in HPV-negative cell lines and tumors (p = 0.002), we 
compared the prognosis for this pattern with the prognosis associated with HPV-
positive tumors characterized by moderate nuclear Wig-1 expression and found the 
prognosis (p = 0.049) to be worse for the former group (HPV-negative cell lines with 
high nuclear Wig-1 expression). Moreover, we found that HPV-negative tumors 
characterized by negative cytoplasmic Wig-1 staining were associated with worse 
prognosis than HPV-positive tumors characterized by positive cytoplasmic Wig-1 
staining (p = 0.033). 
How does high nuclear WIG-1 expression contribute to progression of cervical cancer? 
Our previous results indicate that WIG-1 has a pro-survival function. WIG-1 may 
stimulate cell proliferation and antagonize cell death through up regulation of putative 
mRNA targets such as N-Myc, c-Fos, c-Jun and Cyclin D1, and down regulation of the 
pro-apoptotic Fas (Vilborg et al.2009; Vilborg et al. 2012; Bersani et al., manuscript in 
preparation). Thus, it is plausible that high nuclear Wig-1 expression in tumor cells 
drives cell proliferation through stabilization of pro-growth mRNA targets and 
destabilization of pro-apoptotic mRNA targets. However, the exact roles of nuclear and 
cytoplasmic Wig-1 remain to be elucidated. 
Since WIG-1 is a p53 target gene, the question arises whether WIG-1 expression 
correlates with TP53 status in tumors and/or with presence of HPV, which encodes the 
E6 protein that targets p53 for degradation. The TP53 gene is more frequently mutated 
in HPV-negative than in HPV-positive cervical cancer cell lines and tumors 
(Tommasino et al. 2003). Among the 8 cervical cancer cell lines that we studied, the 
only two HPV-negative cancer cell lines, C-33A and HT-3, both carry the TP53 
mutation. The TP53 status of the cervical carcinomas in our study has not been 
determined. Further studies to determine TP53 status in all tumor samples and to 
examine the correlation between WIG-1 expression and TP53 status are required. Yet, 
A B 
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it should be noted that TP53 is not the only transcription factor that might regulate 
WIG-1. Indeed, we detected WIG-1 protein in all cervical cell lines irrespective of 
TP53 status or genomic gain of the WIG-1 gene. According to Pscan 
(http://159.149.109.9/pscan), several other potential transcription factors, such as SOX, 
may induce WIG-1 expression (Vilborg et al. 2011). The finding that elevated WIG-1 
expression does not correlate with functional TP53 indicates that WIG-1 expression 
also depends on other mechanisms, in addition to direct TP53-mediated transcriptional 
transactivation. 
In summary, moderate to high Wig-1 protein expression is common in cervical cancer 
tissue, especially in the nucleus. Nuclear Wig-1 expression was significantly higher in 
samples of ADC compared with SCC. HPV-negative cervical tumors showed 
significantly higher nuclear Wig-1 expression than HPV-positive tumors. High nuclear 
expression in combination with negative cytoplasmic Wig-1 expression is associated 
with poor prognosis, whereas moderate nuclear expression in combination with positive 
cytoplasmic expression is associated with better prognosis. Amplifications in 3q occur 
in cervical cancer cells, but WIG-1 is not the primary target for driving 3q gains 
according to our SKY, CGH, FISH and Southern blotting analyses. 
In conclusion, from the clinical standpoint it is very important to identify women who 
remain at risk of developing cervical cancer by finding early markers that permit rapid 
and focused preventive action, and to elucidate the factors that influence development 
of cancer in both HPV-infected and HPV-negative women. Understanding the 
molecular mechanisms underlying carcinogenesis in cervical cancer to improve early 
diagnosis, differential diagnosis, and evaluation of tumor aggressiveness, as well as to 
improve molecular markers for screening is crucial. Molecular markers will help 
differentiate between benign disease and malignancy, and thereby prove useful in 
clinical practice. The finding that Wig-1 protein expression is higher in HPV-negative 
cervical carcinoma suggests a possible role for WIG-1 in HPV-negative cervical 
carcinogenesis. Moderate nuclear Wig-1 expression and positive cytoplasmic Wig-1 
expression are associated with better survival rates, indicating that balanced Wig-1 
expression may be able to counter tumor growth. These findings may well contribute to 
optimization of current tumor diagnostics and pave the way for development of new 
treatments. 
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6 CONCLUSIONS 
6.1 PAPER I 
We evaluated the relationship between p16INK4a and Ki-67 expression in cervical 
adenocarcinomas in a series of 101 histological sections and correlated the findings 
with presence of HPV infection and clinical course. We found lower levels of p16INK4a 
tumor suppressor protein in poorly differentiated tumors than in higher differentiated 
tumors and higher levels in HPV-positive tumors than in HPV-negative tumors. Some 
HPV-negative tumors express p16INK4a, indicating HPV-independent mechanisms that 
lead to p16INK4a overexpression in these tumors. The finding that 40% of HPV-negative 
cases lacked detectable p16INK4a suggests that impaired gene expression may contribute 
to carcinogenesis in these cases. Loss of functional p16INK4a could be either the cause 
or the effect of uncontrolled proliferation. Higher levels of the MIB-1 proliferation 
marker were associated with worse outcome. Higher MIB-1 levels are seen in tumors 
with lower histological grade and higher tumor stage at diagnosis.  
6.2 PAPER II 
Detection of E6/E7 mRNA expression using the real-time nucleic acid sequence-based 
amplification assay (NASBA) PreTect HPV-Proofer was compared with results of 
HPV DNA detection in 98 paraffin-embedded samples from patients with cervical 
adenocarcinoma. We discovered that E6/E7 oncogene expression analysis may provide 
a more objective test for assessment of neoplastic glandular cells. E6/E7 mRNA testing 
is as feasible as HPV DNA testing to detect HR-HPV in paraffin-embedded samples of 
cervical adenocarcinoma. Most cervical adenocarcinomas are HPV-positive, therefore 
E6/E7mRNA as an objective marker has the potential to identify women with the 
disease. Despite the limited number of HPV types included, the assay has the ability to 
detect almost all HPV-related cervical adenocarcinomas. Further studies may reveal 
whether the clinical performance of the E6/E7 mRNA assay will be of prognostic value 
in management of cervical adenocarcinoma. 
6.3 PAPER III 
In this study, LRIG protein immunoreactivity was evaluated in 86 cervical 
adenocarcinomas. Both high staining intensity of LRIG1-positive cells and a high 
proportion of LRIG3-positive cells were significantly associated with patient survival, 
and positive correlations were found between both LRIG1 and LRIG3 staining intensity 
and HPV status. Since low expression of LRIG1 correlates with worse survival in 
cervical adenocarcinoma, LRIG1 may be of interest as a potential target for treatment. 
However, whether LRIG1 can inhibit tumor growth remains to be determined. 
6.4 PAPER IV 
The p53 target gene WIG-1 (PAG608, ZMAT3) is located on human chromosome 
3q26.32, a region that is frequently amplified in human tumors, including cervical 
cancer. We have examined the status of WIG-1 in cervical carcinoma cell lines and in 
38 cervical tumor samples, including both squamous cell carcinoma or 
adenocarcinoma.  We detected that Wig-1 expression was positively associated with 
age at diagnosis and histological grade. ADC samples had significantly higher nuclear 
Wig-1 levels (than SCC samples. We observed higher nuclear Wig-1 expression in 
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HPV-negative ADC samples. Patients with moderate nuclear Wig-1 expression levels 
and positive cytoplasmic Wig-1 expression in their tumors had a better prognosis. 
Moreover, patients with HPV-positive tumors and positive cytoplasmic Wig-1 
expression had better survival rate. These results are consistent with a growth-
promoting and/or anti-cell death function of nuclear Wig-1 and suggest that Wig-1 
expression can serve as a prognostic marker in cervical carcinoma. 
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7 FUTURE PERSPECTIVE 
In recent years evidence has accumulated that combined detection of p16INK4a and Ki-
67, using a single immunocytochemistry kit (CINtec PLUS), can help to predict high-
grade or invasive lesions and this methodology is nearing clinical application. Most of 
the studies were carried out on squamous lesions (Petry et al. 2011; Schmidt et al. 
2011; Wentzensen et al.2012). The studies approaching the predictive value of dual 
staining in glandular lesions are small in scope and few in number. However, the 
limited evidence shows a close association between a positive test result and 
subsequent diagnosis of invasive or pre-invasive cervical glandular lesions 
(Samarawardana et al. 2011; Ravarino et al.2012) and the potential to increase 
specificity of HPV testing when used to supplement regular testing (Singh et al.2012). 
An interesting next step would be to analyze the potential of this combination test to 
serve as a marker for cervical adenocarcinoma and its precursor lesions in a larger 
cohort and to address both cytological and histological considerations. 
mRNA cytology testing to triage women with minor cytological abnormalities such as 
ASCUS, or positive DNA testing to detect CIN2+ have been shown to be more specific 
but less sensitive for evaluating squamous lesions  (Verdoot et al. 2013; Stoler et al. 
2013; Perez Castro et al. 2013; Waldström et al. 2012) and less reliable for follow-up 
(Persson et al. 2012). Most studies that use mRNA testing for screening or follow-up 
were not specifically concerned with glandular lesions, which presents an opportunity 
to investigate these methods as a potential tool for triage and follow-up of glandular 
lesions. 
LRIG proteins have been evaluated in squamous cell cancer and precursor lesions, 
showing a correlation between an increase in LRIG1 and LRIG2 expression and 
increasing grade of CIN (Lindström et al. 2011). LRIG1 and LRIG2 have also been 
identified as prognostic markers for early stage SCC (Lindström et al. 2008; Hedman et 
al. 2010). Our next step would be to examine expression of the three LRIG proteins in 
precursor lesion tissue sections and carry out cytological evaluation. 
Our studies of WIG-1 in cervical cancer open the door to questions that can be 
answered by follow-up experimental studies. Previous results indicate that WIG-1 may 
stimulate cell proliferation and antagonize cell death through up regulation of putative 
mRNA targets such as N-My, c-Fos, c-Jun and Cyclin D1, and down regulation of the 
pro-apoptotic Fas (Vilborg et al. 2009; Vilborg et al. 2012; Bersani et al., manuscript in 
preparation). Thus, it is plausible that high nuclear Wig-1 expression in tumor cells 
drives cell proliferation through stabilization of pro-growth mRNA targets and 
destabilization of pro-apoptotic mRNA targets. The exact roles of nuclear and 
cytoplasmic Wig-1 and their correlation with survival, independent of HPV status, need 
to be further elucidated.  
Because WIG-1 is a p53 target gene, the question arises whether Wig-1 expression 
correlates with TP53 status and presence of HPV in tumors, since HR-HPV E6 protein 
targets p53 for degradation. The TP53 gene is more frequently mutated in HPV-
negative than in HPV-positive cervical cancer cell lines and tumors (Tommasino et al. 
2003). Among the 8 cervical cancer cell lines that we studied, the only two HPV-
negative cancers cell lines, C-33A and HT-3, both carry the TP53 mutation. The TP53 
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status of the cervical carcinomas in our study has not been determined. Further studies 
are required to examine TP53 status in all tumor samples so that Wig-1 expression can 
be correlate with TP53 status. The natural antisense transcript Wrap53 is another 
interesting potential marker in this context. It is encoded by the Wrap gene located on 
chromosome 17 and directly overlapping the first exon of TP53. The WRAP53 gene 
gives rise to an antisense transcript that regulates the actions of the tumor suppressor 
TP53 and encodes for a protein with its own oncogenic properties. 
More effective and reliable markers to predict women at risk for developing cervical 
cancer, especially adenocarcinoma, are clearly needed. Knowledge in this field has 
grown immensely in recent decades and initial success was achieved through the 
introduction and improvement of cytological screening, supplemented by HPV testing, 
and by the introduction of new biomarkers. Studies indicate that the first generation of 
HPV vaccines targeting HPV 16 and 18 could prevent at least two-thirds of cervical 
cancers and precursor lesions. Through a combination of vaccination against HPV and 
further improvements in detecting precursor lesions of cervical cancer using molecular 
markers in screening programs, this cancer may become the most preventable on a 
global scale. 
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